



## **Clinical Study Protocol**

NCT Number: NCT05543174

Title: An Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-625 in the Treatment of Subjects with Alagille Syndrome

Study Number: TAK-625-3001

Document Version and Date: Amendment 02 / 08-Dec-2022

Certain information within this document has been redacted (ie, specific content is masked irreversibly from view) to protect either personally identifiable information or company confidential information.

**TAKEDA PHARMACEUTICALS**  
**PROTOCOL**

**An Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-625 in the  
Treatment of Subjects with Alagille Syndrome**

**Short Title**

**TAK-625 for the Treatment of Alagille Syndrome (ALGS)**

**Sponsor:** Takeda Pharmaceutical Company Limited  
1-1, Doshomachi 4-chome, Chuo-ku, Osaka, Japan 540-8645

**Study Number:** TAK-625-3001

**IND Number:** Not Applicable      **EudraCT Number:** Not Applicable

**Compound:** TAK-625

**Date:** 08 Dec 2022      **Version/Amendment Number:** Amendment 02

**Amendment History:**

<b>Date</b>	<b>Amendment Number</b>	<b>Amendment Type</b>	<b>Region</b>
08 Dec 2022	02	Substantial	All sites
15 Jul 2022	01	Nonsubstantial	All sites
18 Apr 2022	Initial version	Not applicable	All sites

## **1.0 ADMINISTRATIVE INFORMATION AND PRINCIPLES OF CLINICAL STUDIES**

### **1.1 Contacts and Responsibilities of Study-Related Activities**

A separate contact information list will be provided to each site (see the annexes).

Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

## **1.2 Principles of Clinical Studies**

This study will be conducted with the highest respect for the individual subjects in accordance with the requirements of this study protocol and also in accordance with the following:

- The ethical principles that have their origin in the Declaration of Helsinki.
- International Council for Harmonisation (ICH) E6 (R2) Good Clinical Practice (GCP): Consolidated Guideline.
- All applicable laws and regulations, including, without limitation, data privacy laws, clinical trial disclosure laws, and regulations.
- “Ministerial Ordinance Concerning the Standards for the Conduct of Clinical Trials of Medicinal Products” (Ministry of Health, Labour and Welfare [MHLW] Ordinance No. 28, 27 March 1997; hereinafter referred to as “the GCP Ordinance”).
- “Ministerial Ordinance that Partially Revises the Ministerial Ordinance Concerning the Standards for the Conduct of Clinical Trials of Medicinal Products” (hereinafter referred to as “the revised GCP Ordinance”).
- Pharmaceutical Affairs Law.


After the marketing approval of TAK-625 is obtained in Japan, this study can be continued as a post-marketing clinical study in accordance with Good Post-marketing Study Practice for medical products (MHLW Ordinance No. 171, 20 December 2004) in addition to above.

## **SIGNATURES**

The signature of the responsible Takeda medical officer and other signatories, as applicable can be found on the signature page.

Electronic Signatures are provided on the last page of this document.

 Date

 Date  Date

## **INVESTIGATOR AGREEMENT**

I confirm that I have read and understand this protocol, the investigator's brochure, prescribing information, and any other product information provided by the sponsor. I agree to conduct this study in accordance with the requirements of this protocol and also to protect the rights, life, dignity, integrity, confidentiality of personal information, safety, privacy, and well-being of study participants in accordance with the following:

- The ethical principles that have their origin in the Declaration of Helsinki.
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Good Clinical Practice.
- All applicable laws and regulations, including, without limitation, data privacy laws and regulations.
- Regulatory requirements for reporting serious adverse events as defined in this protocol.
- Terms outlined in the clinical study site agreement.
- Responsibilities of the investigator as described in this protocol.

I understand that the information in this protocol is confidential and should not be disclosed, other than to those directly involved in the execution or the scientific/ethical review of the study, without written authorization from the sponsor. It is, however, permissible to provide the information contained herein to a potential participant to obtain their informed consent to participate.

I understand that failure to comply with the requirements of the protocol may lead to the termination of my participation as an investigator for this study.

I understand that the sponsor may decide to suspend or prematurely terminate the study at any time for whatever reason; such a decision will be communicated to me in writing. Conversely, should I decide to withdraw from execution of the study, I will communicate my intention immediately in writing to the sponsor.

---

Signature of Investigator

---

Date

---

Investigator Name (print or type)

---

Investigator's Title

---

Location of Facility (City, State/Province)

---

Location of Facility (Country)

### **1.3 Protocol Amendment 02 Summary of Changes**

This section describes the changes in the protocol amendment 02.

The primary reasons for this amendment are to:

- Revise the lower age limit for enrollment in this study from 1 year of age to 1 month of age based on the results of an interim analysis of Study MRX-801.
- Provide the status and results of an interim analysis of Study MRX-801 in subjects <12 months of age with ALGS or familial intrahepatic cholestasis (PFIC).
- Provide the detailed information on the administration of concomitant sodium phenylbutyrate.
- Provide the exceptions in procedures of blood sampling for subjects who are too small to collect enough amount of blood.
- Provide the procedures of dilution of study drug for infants with a body weight <5 kg.
- Clarify the fasting time before blood sampling.
- Clarify the procedures of clinical laboratory tests.
- Add vitamin K to clinical symptoms of lipid soluble vitamin (LSV) deficiency.
- Any minor changes (grammatical and editorial changes, correction of inconsistencies, clerical errors, and typographical errors) are included for clarification purposes only.

The following is a summary of the changes made in this amendment.

<b>Protocol Amendment 02</b>		
<b>Summary of Changes</b>		
<b>Sections (on the current version) Affected by Change</b>	<b>Description of Each Change and Rationale</b>	
<b>Location</b>	<b>Description</b>	<b>Rationale</b>
• <a href="#">Section 4.1.3 Key Clinical Experience</a>	Added the text “For subjects with ALGS, mainly 5 phase 2 studies, LUM001-301, LUM001-302, LUM001-303, LUM001-304, and LUM001-305, have been completed outside Japan.”	Description adjustment: to elaborate the status/situation of clinical experiences.

Protocol Amendment 02		
Summary of Changes		
Sections (on the current version) Affected by Change	Description of Each Change and Rationale	
<i>Location</i>	<i>Description</i>	<i>Rationale</i>
• <a href="#">Section 4.1.3 Key Clinical Experience</a>	Added the text “In addition, one phase 2 study, MRX-801, is ongoing outside Japan for patients <12 months of age with ALGS or PFIC.”	To provide the information on Study MRX-801 for patients <12 months of age with ALGS or PFIC.
• <a href="#">Section 4.1.3.1 Pharmacokinetics in Clinical Studies</a>	Added the text “In addition, the mean (standard deviation [SD]) 2.5 hours after dosing TAK-625 concentration was 0.54 (0.62) ng/mL in subjects <12 months of age with ALGS. This low TAK-625 concentration result is consistent with previous result in subjects ≥12 months of age who were administered TAK-625.”	To provide the PK result in subjects <12 months of age with ALGS enrolled in Study MRX-801.
• <a href="#">Section 4.1.3.2 Study LUM001-304 (Phase 2 Study)</a>	Added the words “(Phase 2 Study)” to the section title.	Description adjustment: to clarify the phase of study.
• <a href="#">Section 4.1.3.3 Study MRX-801 (Phase 2 Study)</a>	Added a section to describe the results summary of an interim analysis of Study MRX-801.	To provide the results of an interim analysis of Study MRX-801.
• <a href="#">Section 4.2 Rationale for the Proposed Study</a>	Added descriptions on the rationale for the enrollment of patients ≥1 month of age in this study.	To revise the lower age limit for enrollment (inclusion criteria) based on the results of an interim analysis of Study MRX-801.

Protocol Amendment 02		
Summary of Changes		
Sections (on the current version) Affected by Change	Description of Each Change and Rationale	
<i>Location</i>	<i>Description</i>	<i>Rationale</i>
<ul style="list-style-type: none"> <li>● [REDACTED]</li> <li>● Section 9.1.7.2 Serum Bile Acids and Other Cholestasis Biomarkers</li> <li>● Section 9.1.11 Procedures for Clinical Laboratory Samples (Table 9.a) (Footnote a)</li> <li>● [REDACTED]</li> <li>● [REDACTED]</li> </ul>	Added a note “* FGF-19 and autotaxin are not mandatory, if the subjects are too small to collect enough amount of blood.”	To clarify the exceptions for laboratory tests in subjects who are too small to collect enough amount of blood.
<ul style="list-style-type: none"> <li>● Section 6.1 Study Design</li> <li>● Section 2.0 Study Summary (Subject Population)</li> </ul>	Revised the age of defined study population of this study from “1 year of age or older” to “1 month of age or older”.	To revise the lower age limit for enrollment (inclusion criteria) based on the results of an interim analysis of Study MRX-801.
<ul style="list-style-type: none"> <li>● Section 6.2 Justification for Study Design, Dose, and Endpoints (Justification for Study Population)</li> </ul>	Removed the words “who are 1 year of age or older” after “The study population is defined as Japanese patients with ALGS”.	To revise the age and to merge the words with the next text.
<ul style="list-style-type: none"> <li>● Section 6.2 Justification for Study Design, Dose, and Endpoints (Justification for Study Population)</li> </ul>	Added the text “Although the safety of TAK-625 was confirmed in subjects <12 months of age with ALGS with moderate to severe cholestasis enrolled in Study MRX-801, the lower age limit for enrollment in this study is set to be 1 month of age, in consideration of preventing the patients from being exposed to the amount of PG in TAK-625 over the maximum daily dose limit of PG specified in the guidance by the EMA.”	To revise the lower age limit for enrollment (inclusion criteria) based on the results of an interim analysis of Study MRX-801.

Protocol Amendment 02		
Summary of Changes		
Sections (on the current version) Affected by Change	Description of Each Change and Rationale	
Location	Description	Rationale
• <a href="#">Section 6.2 Justification for Study Design, Dose, and Endpoints</a> (Justification for Study Population)	Removed the words “, based on the fact that the GI tract is fully mature at 1 year in humans and higher plasma exposures were observed in rats with immature GI tracts in juvenile toxicokinetic studies”.	To remove the redundant explanation.
• <a href="#">Section 6.2 Justification for Study Design, Dose, and Endpoints</a> (Justification for Dose and Regimen of Study Drug)	Removed the words “(ie, $\mu\text{g}/\text{kg}$ )” from the text “TAK-625 is provided as an oral solution that is dosed on a weight basis (ie, $\mu\text{g}/\text{kg}$ )”.	Description adjustment.
• <a href="#">Section 6.2 Justification for Study Design, Dose, and Endpoints</a> (Justification for Dose and Regimen of Study Drug)	Updated the wording “1 year of age” to “12 months of age” before the words “on treatment for over 5 years”.	Description adjustment.
• <a href="#">Section 6.2 Justification for Study Design, Dose, and Endpoints</a> (Justification for Dose and Regimen of Study Drug)	Added the text “Improvements in pruritus and sBA were observed and the safety of TAK-625 was confirmed in infants <12 months of age with ALGS in the ongoing Study MRX-801, in which infants <12 months of age with ALGS or PFIC had been enrolled (the efficacy results in subjects <12 months of age with PFIC are not yet available).”	To provide the results of an interim analysis of Study MRX-801 and to clarify that the results in subjects with PFIC in Study MRX-801 are not yet available.
• <a href="#">Section 7.1 Inclusion Criteria</a> (Inclusion Criteria #2) • <a href="#">Section 2.0 Study Summary</a> (Main Criteria for Inclusion)	<ul style="list-style-type: none"> <li>Revised the lower weight limit from <math>\geq 5 \text{ kg}</math> to <math>\geq 3 \text{ kg}</math>.</li> <li>Revised the lower age limit from <math>\geq 1 \text{ year of age}</math> to <math>\geq 1 \text{ month of age}</math>.</li> <li>Added the text that defined the gestational age and postmenstrual age for subjects &lt;12 months of age.</li> </ul>	<ul style="list-style-type: none"> <li>To revise the lower weight limit for enrollment in this study from <math>\geq 5 \text{ kg}</math> to <math>\geq 3 \text{ kg}</math>.</li> <li>To revise the lower age limit for enrollment in this study from <math>\geq 1 \text{ year of age}</math> to <math>\geq 1 \text{ month of age}</math>.</li> <li>To provide the gestational age and postmenstrual age for subjects &lt;12 months of age.</li> </ul>

Protocol Amendment 02		
Summary of Changes		
Sections (on the current version) Affected by Change	Description of Each Change and Rationale	
<i>Location</i>	<i>Description</i>	<i>Rationale</i>
<ul style="list-style-type: none"> <li>Section 7.1 Inclusion Criteria (Inclusion Criteria #10)</li> <li>Section 2.0 Study Summary (Main Criteria for Inclusion)</li> <li>Section 9.1.2 Eligibility Assessment</li> <li>Section 9.3.1 Screening Period</li> </ul>	Added the text “Since it is difficult to evaluate pruritus in infants, subjects <12 months of age at screening whose pruritus is unavoidably difficult to be evaluated are not necessarily required to meet the above score.”	To revise the lower age limit for enrollment in this study from $\geq 1$ year of age to $\geq 1$ month of age.
<ul style="list-style-type: none"> <li>Section 7.5.1.2 Permitted Concomitant Medications, Procedures, and Treatments</li> </ul>	Added the information on the temporary dose adjustments and dose adaptations of sodium phenylbutyrate.	To provide the detailed information on the administration of concomitant sodium phenylbutyrate.
<ul style="list-style-type: none"> <li>Section 7.5.2 Diet, Fluid, and Activity Control</li> <li>Section 8.1.1.1 Study Drug</li> <li>Section 8.1.3 Dose and Regimen</li> <li>[REDACTED]</li> </ul>	Added the information on the at-home dilution of study drug for infants with a body weight <5 kg.	To provide the necessity of dilution of study drug for infants with a body weight <5 kg and to provide the procedures of the dilution.
<ul style="list-style-type: none"> <li>Section 7.5.2 Diet, Fluid, and Activity Control</li> <li>Section 9.1.7.2 Serum Bile Acids and Other Cholestasis Biomarkers</li> <li>[REDACTED]</li> <li>[REDACTED]</li> </ul>	Amended the texts that defined the fasting time before blood sampling.	To clarify the fasting time and to add the required fasting time for subjects <12 months of age.
<ul style="list-style-type: none"> <li>Section 8.1.1.1 Study Drug</li> </ul>	Removed the word “TAK-625” from “(TAK-625; formerly maralixibat, SHP625, LUM001)”.	Description adjustment.

Protocol Amendment 02		
Summary of Changes		
Sections (on the current version) Affected by Change	Description of Each Change and Rationale	
<i>Location</i>	<i>Description</i>	<i>Rationale</i>
• Section 8.1.1.2 Packaging	<p>Removed the words “and bottle adapters (if needed)”.</p> <p>Added the text “Bottle adapters and equipment for at-home dilution will also be supplied where required.”</p>	To clarify the operating procedure.
• Section 9.1.11 Procedures for Clinical Laboratory Samples (Table 9.a)	<ul style="list-style-type: none"> <li>Removed footnote “a” from “Lipid Panel”, “Cholestasis Biomarkers”, “and Lipid Soluble Vitamins”.</li> <li>Added footnote “b” for RBP.</li> </ul>	To move the footnote for “Lipid Panel”, “Cholestasis Biomarkers”, “and Lipid Soluble Vitamins” to Appendix B, and to provide the explanation on the measurement of RBP for subjects <12 months of age.
• Section 9.1.20.1 Collection of Blood for PK Sampling • [REDACTED] • [REDACTED]	Added the text “Postdose PK samples should be collected in preference to predose PK samples, if the subjects are too small to collect enough amount of blood.”	To clarify the operating procedure.
• Section 10.4.5 Safety Monitoring for LSVs	Added the words “(refer to Appendix B)” after the text “blood samples will be obtained at the study visit before the daily dose of vitamins is administered”.	To clarify the operating procedure.
• Section 10.4.5 Safety Monitoring for LSVs	Added “vitamin K” to the clinical symptoms of LSV deficiency.	To clarify the clinical symptoms of LSV deficiency.
[REDACTED]		

<b>Protocol Amendment 02</b>		
<b>Summary of Changes</b>		
<b>Sections (on the current version) Affected by Change</b>	<b>Description of Each Change and Rationale</b>	
<i>Location</i>	<i>Description</i>	<i>Rationale</i>

Property of Takeda: For non-commercial use only and subject to applicable Terms of Use

## TABLE OF CONTENTS

1.0	ADMINISTRATIVE INFORMATION AND PRINCIPLES OF CLINICAL STUDIES .....	2
1.1	Contacts and Responsibilities of Study-Related Activities .....	2
1.2	Principles of Clinical Studies.....	3
1.3	Protocol Amendment 02 Summary of Changes.....	5
2.0	STUDY SUMMARY.....	19
3.0	LIST OF ABBREVIATIONS.....	24
3.1	Corporate Identification .....	27
3.2	Study Definitions .....	27
4.0	INTRODUCTION .....	28
4.1	Background .....	28
4.1.1	Drug Overview .....	28
4.1.2	Disease Background .....	28
4.1.3	Key Clinical Experience.....	29
4.1.3.1	Pharmacokinetics in Clinical Studies.....	29
4.1.3.2	Study LUM001-304 (Phase 2 Study).....	30
4.1.3.3	Study MRX-801 (Phase 2 Study).....	31
4.2	Rationale for the Proposed Study .....	32
4.3	Benefit/Risk Profile .....	33
5.0	STUDY OBJECTIVES AND ENDPOINTS .....	33
5.1	Objectives .....	33
5.1.1	Primary Objectives .....	33
5.1.2	Secondary Objectives .....	33
5.2	Endpoints .....	34
5.2.1	Primary Endpoint.....	34
5.2.2	Secondary Endpoints .....	34
5.2.2.1	Key Secondary Endpoints .....	34
5.2.2.2	Secondary Endpoints.....	34
5.2.3	Safety Endpoints.....	34
5.2.5	PK Endpoint .....	36
6.0	STUDY DESIGN AND DESCRIPTION .....	36
6.1	Study Design.....	36
6.2	Justification for Study Design, Dose, and Endpoints .....	39

6.3	Premature Termination or Suspension of Study or Study Site .....	40
6.3.1	Criteria for Premature Termination or Suspension of the Study .....	40
6.3.2	Criteria for Premature Termination or Suspension of Study Sites .....	40
6.3.3	Procedures for Premature Termination or Suspension of the Study or the Participation of Study Site(s).....	41
6.3.4	Duration of an Individual Subject's Study Participation.....	41
6.3.5	End of Study/Study Completion Definition and Planned Reporting.....	41
7.0	SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS .....	42
7.1	Inclusion Criteria .....	42
7.2	Exclusion Criteria .....	43
7.3	Excluded Medications.....	45
7.3.1	Justification of Excluded Medications .....	45
7.4	Excluded Procedures and Treatments .....	45
7.4.1	Justification of Excluded Procedures and Treatments.....	45
7.5	On Study Restrictions .....	46
7.5.1	Concomitant Medications, Procedures, and Treatments .....	46
7.5.1.1	Prohibited Concomitant Medications, Procedures, and Treatments .....	46
7.5.1.2	Permitted Concomitant Medications, Procedures, and Treatments .....	46
7.5.1.3	LSVs.....	47
7.5.2	Diet, Fluid, and Activity Control.....	47
7.6	Criteria for Discontinuation or Withdrawal of a Subject.....	47
7.7	Procedures for Discontinuation or Withdrawal of a Subject .....	48
8.0	CLINICAL STUDY MATERIAL MANAGEMENT .....	49
8.1	Study Drug and Materials .....	49
8.1.1	Dosage Form, Manufacturing, Packaging, and Labeling .....	49
8.1.1.1	Study Drug .....	49
8.1.1.2	Packaging .....	49
8.1.1.3	Labeling.....	50
8.1.2	Storage .....	50
8.1.3	Dose and Regimen.....	50
8.1.4	Stopping Criteria of Dosing.....	51
8.1.5	Overdose and Medication Error .....	51
8.2	Study Compliance .....	52
8.3	Study Drug Assignment and Dispensing Procedures .....	52
8.4	Accountability and Destruction of Sponsor-Supplied Drugs.....	52

<b>9.0</b>	<b>STUDY PLAN</b>	<b>53</b>
<b>9.1</b>	<b>Study Procedures</b>	<b>53</b>
9.1.1	Informed Consent Procedure	53
9.1.2	Eligibility Assessment	53
9.1.3	Demographics, Medical History, Disease History, and Medication History/Prior Treatment Procedure	54
9.1.4	Physical Examination Procedure	54
9.1.5	Weight, Height, and BMI	54
9.1.6	Vital Sign Procedure	55
9.1.7	Primary Efficacy Measurement	55
9.1.7.1	eDiary	55
9.1.7.2	Serum Bile Acids and Other Cholestasis Biomarkers	56
9.1.8	Other Efficacy Measurement	56
9.1.9	Documentation of Concomitant Medications	58
9.1.10	Documentation of Concurrent Medical Conditions (Complication)	58
9.1.11	Procedures for Clinical Laboratory Samples	58
9.1.12	Pregnancy Test	61
9.1.13	Contraception and Pregnancy Avoidance Procedure	61
9.1.13.1	Male Subjects and Their Female Partners	61
9.1.13.2	Female Subjects and Their Male Partners	61
9.1.13.3	Definitions and Procedures for Contraception and Pregnancy Avoidance	61
9.1.13.4	General Guidance with Respect to the Avoidance of Pregnancy	63
9.1.14	Pregnancy	63
9.1.15	ECG Procedure	64
9.1.16	Ultrasound Liver Imaging	64
9.1.17	AE Collection	64
9.1.18	Other Safety Evaluation	65
9.1.19	Genetic Testing (ALGS Genotype)	65
9.1.20	PK Sample Collection and Analysis	65
9.1.20.1	Collection of Blood for PK Sampling	65

9.1.21 Documentation of Screen Failure .....	66
9.1.22 Documentation of Study Entrance.....	66
9.2 Monitoring Subject Treatment Compliance.....	66
9.3 Schedule of Observations and Procedures.....	67
9.3.1 Screening Period.....	67
9.3.2 Dose Escalation Period.....	69
9.3.2.1 Visit in the Dose Escalation Period.....	69
9.3.2.2 Phone Calls in the Dose Escalation Period .....	70
9.3.3 Stable Dosing Period .....	70
9.3.3.1 Visits in the Stable Dosing Period .....	70
9.3.3.2 Phone Calls the Stable Dosing Period.....	71
9.3.4 ET .....	71
9.3.5 Follow-up Dosing Period .....	72
9.3.6 Safety Follow-up .....	73
9.3.7 Post Study Care .....	73
9.3.8 Alternative Approaches to Study Procedures and Data Collection Due to Coronavirus Disease 2019 .....	73
9.4 Biological Sample Retention and Destruction.....	75
10.0 AES .....	76
10.1 Definitions.....	76
10.1.1 Pretreatment Events.....	76
10.1.2 AEs .....	76
10.1.3 Additional Points to Consider for AEs .....	76
10.1.4 SAEs .....	78
10.1.5 AECIs .....	78
10.1.6 Intensity of AEs .....	79
10.1.7 Causality of AEs.....	79
10.1.8 Relationship to Study Procedures.....	79
10.1.9 Start Date .....	79
10.1.10 Stop Date .....	80
10.1.11 Frequency .....	80
10.1.12 Action Concerning Study Drug .....	80
10.1.13 Outcome .....	81
10.2 Procedures.....	81
10.2.1 Collection and Reporting of AEs .....	81

10.2.1.1	AE Collection Period .....	81
10.2.1.2	AE Reporting .....	81
10.2.2	Collection and Reporting of SAEs .....	82
10.3	Follow-up of SAEs .....	83
10.3.1	Safety Reporting to Investigators, IRBs, and Regulatory Authorities .....	83
10.4	Safety Monitoring Rules .....	84
10.4.1	General Guidelines .....	84
10.4.2	Close Monitoring Criteria for Liver Parameters .....	84
10.4.3	Guidelines for Interruption of Study Drug for Specific Liver Parameters .....	86
10.4.4	Rules for Study Drug Discontinuation Following Abnormalities of Liver Parameters .....	87
10.4.5	Safety Monitoring for LSVs .....	87
10.4.6	Safety Monitoring for Coagulation Panel Results .....	88
10.4.7	Study Medication Discontinuation Rules for Diarrhea .....	88
10.5	Product Complaints .....	88
11.0	STUDY-SPECIFIC COMMITTEES .....	88
12.0	DATA HANDLING AND RECORDKEEPING .....	88
12.1	eCRFs .....	89
12.2	Record Retention .....	90
13.0	STATISTICAL METHODS .....	90
13.1	Statistical and Analytical Plans .....	90
13.1.1	Analysis Sets .....	91
13.1.2	Analysis of Demographics and Other Baseline Characteristics .....	91
13.1.3	Efficacy Analysis .....	91
13.1.3.1	Primary Endpoint .....	91
13.1.3.2	Key Secondary Endpoints and Other Secondary Endpoints .....	91
13.1.3.4	Significance Level and Confidence Coefficient .....	91
13.1.4	PK Analysis .....	92
13.1.5	Safety Analysis .....	92
13.1.5.1	TEAEs .....	92
13.1.5.2	Clinical Laboratory Results, Vital Signs, ECGs, and Physical Examination Findings (Including Body Weight, Height, and BMI) .....	92
13.2	Interim Analysis .....	92
13.3	Determination of Sample Size .....	93

---

13.4	Other Statistical Considerations.....	93
14.0	QUALITY CONTROL AND QUALITY ASSURANCE.....	93
14.1	Study-Site Monitoring Visits .....	93
14.2	Protocol Deviations.....	93
14.3	Quality Assurance Audits and Regulatory Agency Inspections .....	94
15.0	ETHICAL ASPECTS OF THE STUDY .....	94
15.1	IRB Approval.....	94
15.2	Subject Information, Informed Consent, and Subject Authorization .....	95
15.3	Subject Confidentiality .....	96
15.4	Clinical Trial Disclosures and Publication .....	97
15.4.1	Clinical Trial Registration and Results Disclosure .....	97
15.4.2	Publication.....	97
15.5	Insurance and Compensation for Injury.....	97
16.0	DISSEMINATION OF NEW INFORMATION .....	97
17.0	REFERENCES .....	98
18.0	APPENDIX.....	99

Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use


**LIST OF IN-TEXT TABLES**

Table 9.a	Clinical Laboratory Tests.....	60
Table 10.a	Close Monitoring Criteria for Treatment-Emergent Elevated ALT and TSB .....	85
Table 10.b	Guidelines for Interruption of Study Drug for Specific Liver Parameters .....	86

**LIST OF IN-TEXT FIGURES**

Figure 6.a	Schematic of Study Design.....	38
------------	--------------------------------	----

**LIST OF APPENDICES**



## 2.0 STUDY SUMMARY

<b>Name of Sponsor(s):</b> Takeda Pharmaceutical Company Limited	<b>Compound:</b> TAK-625	
<b>Title of Protocol:</b> An Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-625 in the Treatment of Subjects with Alagille Syndrome	<b>IND No.:</b> Not Applicable.	<b>EudraCT No.:</b> Not Applicable.
<b>Study Number:</b> TAK-625-3001	<b>Phase:</b> 3	

### Study Design:

This is a phase 3, multicenter, open-label, uncontrolled study to evaluate the efficacy and safety of TAK-625 in the treatment of Japanese subjects with Alagille syndrome (ALGS). This study consists of the screening period (up to 6 weeks prior to the study administration), 2-week dose escalation period, 46-week stable dosing period, and follow-up dosing period (until TAK-625 is approved or available in Japan commercially, or if the subject withdraws from the study, or if the investigator determines the subject's discontinuation, or if the sponsor stops the program or development in this indication).

- Screening Period (Up to 6 Weeks prior to the Study Administration):

In the screening period, for subjects who do not have documentation of mutation related to ALGS (JAGGED-1 or NOTCH2), genetic testing may be performed, if necessary. The electronic diary (eDiary) for assessing pruritus with the Itch Reported Outcome (ItchRO) instrument will be dispensed and subjects and caregivers will undergo training during the screening visit.

- Dose Escalation Period (2 Weeks: Week 0 to 2):

In the dose escalation period, at the baseline visit (Week 0/Visit 2), subjects will be assessed to confirm continued study eligibility and undergo a physical examination and have urine and blood samples taken. Compliance with ItchRO will be assessed. Study drug for Weeks 1 and 2 will be supplied at the baseline visit to eligible subjects. Subjects will receive the study drug, TAK-625, administered orally once a day (QD). The dose will be increased weekly over a 2-week period up to 400 µg/kg/day QD as follows: dose level 1, 200 µg/kg/day QD for 1 week; and dose level 2, 400 µg/kg/day QD for the remaining duration of the study.

If an individual subject exhibits a treatment-emergent moderate or severe drug-related gastrointestinal (GI) toxicity with 400 µg/kg/day, study drug dose may be lowered to 200 µg/kg/day; later attempts to escalate the dose are permitted during the dose escalation period. This decision should be made in consultation with the medical monitor. If further dose escalations fail during the dose escalation period, the subject will remain on 200 µg/kg/day for the remainder of the study.

- Stable Dosing Period (46 Weeks: Week 3 to 48):

After the dose escalation period, each subject will continue dosing with study drug at the Week 3 dose level, which is either 200 or 400 µg/kg/day, in the stable dosing period. Subjects and caregivers will continue twice daily completion of their ItchRO throughout the period.

- Follow-up Dosing Period (after Week 48):

In the follow-up dosing period, each subject will continue dosing with study drug at the Week 48 dose level, which is either 200 or 400 µg/kg/day. The safety evaluation will be performed in all the subjects every 12 weeks from Week 48 visit until TAK-625 is approved or available in Japan commercially, or if the subject withdraws from the study, or if the investigator determines the subject's discontinuation, or if the sponsor stops the program or development in this indication. Bile acids and ItchRO will be measured to evaluate the long-term effectiveness of TAK-625. For subjects discontinuing early, safety follow-up will be conducted.

- Safety Follow-up (after Final Visit/Early Termination [ET]):

Subjects/caregivers will have a final safety follow-up subject contact (phone call) 7 days after the final study visit or ET visit (except for screen failure).

<b>Primary Objectives:</b> <ul style="list-style-type: none"><li>• To evaluate the efficacy and safety of TAK-625 in subjects with ALGS.</li></ul>	
<b>Secondary Objectives:</b> <ul style="list-style-type: none"><li>• To evaluate the pharmacokinetics (PK) of TAK-625 in subjects with ALGS.</li><li>• To evaluate the efficacy of TAK-625 on biochemical markers of cholestasis and liver disease in subjects with ALGS.</li></ul>	
<b>Subject Population:</b> Japanese patients with ALGS who are 1 month of age or older.	
<b>Number of Subjects:</b> In this study, approximately 5 subjects will be enrolled as targeted sample size.	<b>Number of Sites:</b> Estimated total: approximately 10 sites in Japan.
<b>Dose Levels:</b> Dose level 1: 200 µg/kg/day QD for 1 week. Dose level 2: 400 µg/kg/day QD for the remaining duration of the study.	<b>Route of Administration:</b> Oral
<b>Duration of Treatment:</b> <ul style="list-style-type: none"><li>• <u>Dose Escalation Period:</u> 2 weeks.</li><li>• <u>Stable Dosing Period:</u> 46 weeks.</li><li>• <u>Follow-up Dosing Period:</u> until TAK-625 is approved or available in Japan commercially, or if the subject withdraws from the study, or if the investigator determines the subject's discontinuation, or if the sponsor stops the program or development in this indication.</li></ul>	<b>Period of Evaluation:</b> <ul style="list-style-type: none"><li>• <u>Screening Period:</u> up to 6 weeks.</li><li>• <u>Dose Escalation Period:</u> 2 weeks.</li><li>• <u>Stable Dosing Period:</u> 46 weeks.</li><li>• <u>Follow-up Dosing Period:</u> every 12 weeks after the stable dosing period until TAK-625 is approved or available in Japan commercially, or if the subject withdraws from the study, or if the investigator determines the subject's discontinuation, or if the sponsor stops the program or development in this indication.</li><li>• <u>Safety Follow-up (phone call):</u> 7 days after the final study visit or ET visit (except for screen failure).</li></ul>

**Main Criteria for Inclusion:**

The main criteria for inclusion in this study are as follows:

- The subject is Japanese male or female with a body weight  $\geq 3.0$  kg and who is  $\geq 1$  month of age at the time of informed consent.  
For subjects  $<12$  months of age, gestational age  $\geq 36$  weeks at birth. For subjects born with gestational age between 32 and 36 weeks, a postmenstrual age of  $\geq 36$  weeks is required. Postmenstrual age is defined as the time elapsed between the first day of the last menstrual period and birth plus the time elapsed after birth.
- The subject is diagnosed with ALGS based on the diagnostic criteria outlined below.  
Major clinical criteria/features for ALGS include: cholestasis, consistent cardiac, renal, vascular, ocular, skeletal involvement, or characteristic “Alagille” facies.

ALGS Family History <sup>a</sup>	Paucity	JAGGED1 or NOTCH2 Mutation	Major Clinical Criteria Needed for Diagnosis
Present or Absent	Present	Identified <sup>b</sup>	Any or no features
None (proband)	Absent or unknown	Identified	1 or more features
None (proband)	Present	Not identified <sup>c</sup>	3 or more features
None (proband)	Absent or unknown	Not identified	4 or more features
Present	Absent or unknown	Identified	Any or no features
Present	Present	Not identified	1 or more features
Present	Absent or unknown	Not identified	2 or more features

<sup>a</sup> Family history=ALGS present in a first degree relative.

<sup>b</sup> Identified=JAGGED1 or NOTCH2 mutation identified in clinical laboratory.

<sup>c</sup> Not identified=Not identified on screening, or not screened for.

- The subject has one or more of the following evidences of cholestasis:
  - a. Total serum bile acid (sBA)  $>3\times$  upper limit of the normal range (ULN) for age.
  - b. Direct bilirubin (conjugated)  $>1$  mg/dL.
  - c. Lipid soluble vitamin (LSV) deficiency otherwise unexplainable.
  - d. Gamma-glutamyl transferase (GGT)  $>3\times$ ULN for age.
  - e. Intractable pruritus explainable only by liver disease.
- Caregivers (and age-appropriate subjects) must complete at least 10 eDiary reports (morning or evening) during each of 2 consecutive weeks of the screening period (maximum possible reports=14 per week), even if the subject is an adult (over 18 years old).

Average daily score  $>2$  on the ItchRO questionnaire (maximum possible daily score of 4) for 2 consecutive weeks in the screening period, prior to dosing. A daily score is the higher of the scores for the morning and evening ItchRO. The average daily score is the sum of all daily scores divided by the number of days the ItchRO was completed. Since it is difficult to evaluate pruritus in infants, subjects  $<12$  months of age at screening whose pruritus is unavoidably difficult to be evaluated are not necessarily required to meet the above score.

**Main Criteria for Exclusion:**

The main criteria for exclusion in this study are as follows:

- The subject has chronic diarrhea requiring ongoing intravenous (IV) fluid or nutritional intervention.
- The subject has a previous history of surgical interruption of the enterohepatic circulation.
- The subject has a previous liver transplant.
- The subject decompensated cirrhosis (alanine aminotransferase [ALT]  $>15 \times$  ULN, international normalized ratio [INR]  $>1.5$  [unresponsive to vitamin K therapy], albumin  $<3.0$  g/dL, history or presence of clinically significant ascites, variceal hemorrhage, and/or encephalopathy).
- The subject has a history or presence of other concomitant liver disease.
- The subject has a history or presence of any other disease or condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs, including bile salt metabolism in the intestine (eg, inflammatory bowel disease).
- The subject has a history or presence of gallstones or kidney stones.
- The subject has received bile acid/lipid binding resins or ileal bile acid transporter (IBAT) inhibitors within 28 days prior to screening and throughout the trial.
- The subject who has received sodium phenylbutyrate for less than 6 months at the initiation of screening.

**Main Criteria for Evaluation and Analyses:**

The primary endpoint for this study is the change from Week 18 to 22 of fasting sBA levels.

Key secondary endpoints are as follows:

- Change from baseline to Week 18:
  - Fasting sBA levels.
  - Pruritus as measured by Observer-reported Itch Reported Outcome (ItchRO [Obs]): weekly average severity (based on daily maximum of morning and evening severity scores).
  - Pruritus as measured by ItchRO (Obs): weekly average morning severity.
- Change from Week 18 to 22:
  - Pruritus as measured by ItchRO (Obs): weekly average severity (based on daily maximum of morning and evening severity scores).
  - Pruritus as measured by ItchRO (Obs): weekly average morning severity.

Other secondary endpoints for this study are as follows:

- Change from baseline to Week 18:
  - Pruritus as measured by Patient-reported Itch Reported Outcome (ItchRO [Pt]): weekly average severity (based on daily maximum of morning and evening severity scores).
  - Pruritus as measured by ItchRO (Pt): weekly average morning severity.
  - Liver enzymes (ALT and alkaline phosphatase [ALP]) and bilirubin (total and direct).
- Change from Week 18 to 22:
  - Pruritus as measured by ItchRO (Pt): weekly average severity (based on daily maximum of morning and evening severity scores).
  - Pruritus as measured by ItchRO (Pt): weekly average morning severity.
  - Liver enzymes (ALT and ALP) and bilirubin (total and direct).

**Statistical Considerations:**

Analytical Methods for Primary Endpoint

Primary Analysis: Descriptive statistics and two-sided 95% confidence interval (CI) of mean will be provided based on the intention-to-treat set (ITT).

Secondary Analysis: For supportive analysis, the same analysis as the primary analysis will be performed using the modified intention-to-treat set (MITT) and the per protocol analysis set (PPS) to confirm robustness of the results.

Analytical Methods for Key Secondary Endpoints

Descriptive statistics and two-sided 95% CI of mean will be provided based on the ITT. For supportive analysis, the same analysis as the above analysis will be performed using the PPS to confirm robustness of the results.

Analytical Methods for Secondary Endpoints

Descriptive statistics and two-sided 95% CI of mean will be provided based on the ITT.

**Sample Size Justification:** ALGS is a rare disease. The targeted sample size is approximately 5 subjects based on enrollment feasibility of this population in Japan, rather than power calculation.

### **3.0 LIST OF ABBREVIATIONS**

AE	adverse event
AECI	adverse event of clinical interest
AFP	$\alpha$ -fetoprotein
ALGS	Alagille syndrome
ALP	alkaline phosphatase
ALT	alanine aminotransferase
ANA	antinuclear antibody
ANCOVA	analysis of covariance
[REDACTED]	[REDACTED]
aPTT	activated partial thromboplastin time
ARW	after randomized withdrawal
AST	aspartate aminotransferase
AUC	area under the curve
7 $\alpha$ C4	7 $\alpha$ -hydroxy-4-cholesten-3-one
$\beta$ -hCG	$\beta$ -human chorionic gonadotropin
BID	twice daily
BMI	body mass index
BUN	blood urea nitrogen
CBC	complete blood count
CI	confidence interval
$C_{\max}$	maximum drug concentration
CMV IgM	cytomegalovirus immunoglobulin M
COA	clinical outcomes assessment
COVID-19	coronavirus disease 2019
CPK	creatine phosphokinase
CRO	contract research organization
CSR	clinical study report
CSS	Clinician Scratch Scale
DILI	drug-induced liver injury
DMC	Data Monitoring Committee
DSMB	Data Safety Monitoring Board
EAP	Expanded Access Program
EBV	Epstein-Barr virus
ECG	electrocardiogram
eCRF	electronic case report form
EDC	electronic data capture
eDiary	electronic diary
EMA	European Medicines Agency
EOT	end of treatment

ET	early termination
fBA	fecal bile acid
FDA	Food and Drug Administration
FGF-19	fibroblast growth factor 19
████████	████████
FSH	follicle stimulating hormone
GCP	Good Clinical Practice
GGT	gamma-glutamyl transferase
GI	gastrointestinal
HAV IgM	hepatitis A virus immunoglobulin M
HBs Ag	hepatitis B virus surface antigen
HCC	hepatocellular carcinoma
HCV	hepatitis C virus
HDL-C	high density lipoprotein-cholesterol
HIV	human immunodeficiency virus
HRQoL	health-related quality of life
IB	investigator's brochure
IBAT	ileal bile acid transporter
IC <sub>50</sub>	half maximal (50%) inhibitory concentration
ICH	International Council for Harmonisation
ID	identification
INR	international normalized ratio
IRB	institutional review board
IRT	Interactive Response Technology
ItchRO	Itch Reported Outcome
ItchRO (Obs)	Observer-reported Itch Reported Outcome
	Itch Reported Outcome (Observer)
	(Observer-reported outcome, observer rated Itch Reported Outcome)
ItchRO (Pt)	Patient-reported Itch Reported Outcome
	Itch Reported Outcome (Patient)
	(Patient-reported outcome, patient rated Itch Reported Outcome)
ITT	intention-to-treat set
IUD	intrauterine device
IV	intravenous
LC-MS	liquid chromatography-mass spectrometry
LC-MS/MS	liquid chromatograph-tandem mass spectrometer
LDH	lactate dehydrogenase
LDL-C	low density lipoprotein-cholesterol
LOQ	lower limit of quantification
LS	least squares

LSV	lipid soluble vitamin
LTE	long-term extension
MCH	mean corpuscular hemoglobin
MCHC	mean corpuscular hemoglobin concentration
MCV	mean corpuscular volume
MedDRA	Medical Dictionary for Regulatory Activities
MHLW	Ministry of Health, Labour and Welfare
MHRA	Medicines and Healthcare products Regulatory Agency
MITT	modified intention-to-treat set
MRI	magnetic resonance imaging
MTD	maximum tolerated dose
OL	open-label run-in
PEBD	partial external biliary diversion
[REDACTED]	[REDACTED]
PET	polyethylene terephthalate
PFIC	progressive familial intrahepatic cholestasis
PG	propylene glycol
PK	pharmacokinetics
PMDA	Pharmaceuticals and Medical Devices Agency
PPS	per protocol analysis set
PRO	patient reported outcome
PT	prothrombin time
QD	once a day
QTcB	QT interval corrected using Bazett's formula
QTcF	QT interval corrected using Fridericia's formula
RBP	retinol binding protein
RNA	ribonucleic acid
RWD	randomized withdrawal
SAE	serious adverse event
SAP	statistical analysis plan
sBA	serum bile acid
SD	standard deviation
SE	standard error
SGOT	serum glutamic-oxaloacetic transaminase
SGPT	serum glutamic-pyruvic transaminase
SUSAR	suspected unexpected serious adverse reaction
TEAE	treatment-emergent adverse event
TG	triglycerides
TSB	total serum bilirubin
UK	United Kingdom

ULN	upper limit of the normal range
US	United States
WBC	white blood cell
WHO	World Health Organization
WOCBP	woman/women of childbearing potential

### **3.1 Corporate Identification**

TDC Japan	Takeda Development Center Japan
TDC Asia	Takeda Development Center Asia, Pte Ltd
TDC Europe	Takeda Development Centre Europe Ltd.
TDC Americas	Takeda Development Center Americas, Inc.
TDC	TDC Japan, TDC Asia, TDC Europe and/or TDC Americas, as applicable
Takeda	TDC Japan, TDC Asia, TDC Europe and/or TDC Americas, as applicable

### **3.2 Study Definitions**

#### **Terms**

Duration of Treatment and Duration of Follow-up

End-of-Trial

#### **Definitions**

The study will be continued until TAK-625 is approved or available in Japan commercially, or if the subject withdraws from the study, or if the investigator determines the subject's discontinuation, or if the sponsor stops the program or development in this indication.

The study completion date is defined as the date when the final subject, across all sites, completes their final protocol-defined assessment.

## 4.0 INTRODUCTION

### 4.1 Background

#### 4.1.1 Drug Overview

Ileal bile acid transporter (IBAT) is a transmembrane protein localized on the luminal surface of enterocytes in the terminal ileum and plays a key role in the enterohepatic circulation of bile acids by reabsorbing bile acids. TAK-625 (maralixibat) was designed to be minimally absorbed, therefore maximizing the local exposure of the molecule to the receptor and minimizing systemic exposure of the drug and limiting drug-drug interactions and systemic toxicity. These characteristics include a high molecular weight of 710 Da and the addition of a positively charged quaternary amino moiety that can interact with the negatively charged surface of the enterocyte cell membrane and prevent absorption. TAK-625, a highly potent and selective IBAT inhibitor (half maximal [50%] inhibitory concentration  $[IC_{50}]$ =0.3 nmol/L), inhibits intestinal bile acids reabsorption, thereby increasing fecal bile acid (fBA) excretion and lowering serum bile acid (sBA) levels without systemic exposure.

By virtue of its ability to interrupt enterohepatic circulation by inhibiting bile acid absorption, TAK-625 is being developed as a therapeutic agent for signs and symptoms of cholestatic liver disease. In September 2021, TAK-625 was approved in the United States (US) for the treatment of pruritus associated with Alagille syndrome (ALGS). Clinical studies for progressive familial intrahepatic cholestasis (PFIC) and biliary atresia are currently ongoing outside Japan.

TAK-625 is provided as an oral solution and will be prescribed to a given subject based on body weight ( $\mu\text{g}/\text{kg}$ ). This is the standard dosing regimen for pediatric patients and is supported by clinical experience in development programs for pediatric cholestatic liver disease.

#### 4.1.2 Disease Background

ALGS is a rare genetic, multisystem disease affecting 1 in 100,000 people [1]. In Japan, an estimated frequency is 1 in 30,000 people and there are 200 to 300 diagnosed patients reported based on national survey [2].

In addition to multiple other abnormalities (eg, cardiovascular, skeletal, and ocular), ALGS is typically accompanied by cholestatic liver disease and usually associated with severe pruritus manifesting during infancy and childhood, jaundice, xanthomas, fat malabsorption, failure to thrive, and hepatocellular injury. Debilitating pruritus, xanthomas, and progressive liver disease ultimately lead to the need for surgical interventions, including partial external biliary diversion (PEBD) or liver transplantation. Transplant-free survival in patients with cholestasis related to ALGS was no more than 70% at 10 years and is estimated to be 24% at 18.5 years of age [3]. Liver transplant carries the burden of lifelong immunosuppressive therapy and has significant morbidity and mortality [4]. Left untreated, patients with ALGS have a median life expectancy of approximately 2 decades [1].

Among clinical symptoms of ALGS, pruritus can be severe, even in the absence of jaundice. Elevation of sBA is frequently accompanied by pruritus, and a causal association between pruritus and bile acids is suggested by the following: (1) pruritus can be induced in volunteers by applying topical unconjugated bile acids, deoxycholate, and chenodeoxycholate to the skin; and (2) pruritus can be relieved by surgical interruption of the enterohepatic circulation, which dramatically lowers sBA.

Intractable and pharmacologically recalcitrant pruritus is one of the major morbidities afflicting children with ALGS. Treatment with anti-pruritics and bile salt resins may provide partial relief of pruritus for children with ALGS, but currently available pharmacologic approaches are of limited value. It has been shown that removing bile with surgical procedures such as PEBD substantially reduces pruritus in ALGS [5].

To date, no pharmacologic interventions have been approved to treat ALGS or cholestatic pruritus associated with ALGS in Japan. Since reduction in bile acid concentrations with PEBD has been shown to be associated with improvement in cholestatic pruritus in ALGS, pharmacological diversion of bile acids with an IBAT inhibitor could be an attractive alternative to surgical intervention in ALGS without surgical complications. TAK-625 potentially reduces cholestasis due to ALGS and the related effects of cholestatic pruritus, xanthomas, and growth deficiency by above mechanism.

#### **4.1.3 Key Clinical Experience**

For subjects with ALGS, mainly 5 phase 2 studies, LUM001-301, LUM001-302, LUM001-303, LUM001-304, and LUM001-305, have been completed outside Japan. In addition, one phase 2 study, MRX-801, is ongoing outside Japan for patients <12 months of age with ALGS or PFIC.

##### *4.1.3.1 Pharmacokinetics in Clinical Studies*

In clinical studies evaluating pharmacokinetics (PK), TAK-625 is minimally absorbed, with little detectable unchanged TAK-625 in plasma (lower limit of quantification [LOQ] 0.25 ng/mL) after multiple dosing with TAK-625 at doses  $\leq$ 20 mg. In addition, the mean (standard deviation [SD]) 2.5 hours after dosing TAK-625 concentration was 0.54 (0.62) ng/mL in subjects <12 months of age with ALGS. This low TAK-625 concentration result is consistent with previous result in subjects  $\geq$ 12 months of age who were administered TAK-625.

Concomitant administration of a high-fat meal with a single oral dose of TAK-625 decreased both the rate and extent of absorption. Area under the curve (AUC) and maximum drug concentration ( $C_{max}$ ) of TAK-625 values in the fed state were 64.8% to 85.8% lower relative to oral administration of 30 or 45 mg in fasted conditions.

Fecal excretion was found to be the major route of elimination. Following a single oral dose of 5 mg [ $^{14}C$ ] TAK-625, the majority was recovered in feces, with recovery in whole blood, plasma, or urine accounting for <1%. Three metabolites were detected in feces, but these accounted for <3% of total fecal radioactivity. The remainder of the fecal radioactivity (>94%) was associated with unchanged TAK-625.

#### 4.1.3.2 Study LUM001-304 (Phase 2 Study)

For subjects with ALGS, the efficacy of TAK-625 was assessed in Study LUM001-304, which was a pivotal study in US Food and Drug Administration (FDA) approval of TAK-625 for the treatment of cholestatic pruritus associated with ALGS. Study LUM001-304 consisted of an 18-week open-label run-in (OL) period (OL phase), a 4-week randomized, double-blind, placebo-controlled drug-withdrawal period (randomized withdrawal [RWD] phase), a 26-week stable-dosing period (after randomized withdrawal [ARW] phase), and an optional long-term treatment period (long-term extension [LTE] phase).

#### **Efficacy Results:**

##### 1. sBA

The primary efficacy endpoint was the change from Week 18 to Week 22 in fasting sBA levels. A total of 29 subjects (RWD TAK-625, n=13; RWD placebo, n=16) were included in the intention-to-treat set (ITT), of which 15 subjects (RWD TAK-625, 5 subjects; RWD placebo, 10 subjects) were included in modified intention-to-treat set (MITT).

Using an analysis of covariance (ANCOVA) model for MITT, subjects in the RWD placebo group had significant increases in sBA from Week 18 to Week 22, with a least squares (LS) mean (standard error [SE]) increase of 95.55 (30.488)  $\mu\text{mol/L}$  ( $p=0.0086$ ), while subjects in the RWD TAK-625 group had no significant change (LS mean [SE] decrease, or improvement of 21.73 [43.125]  $\mu\text{mol/L}$ ,  $p=0.6234$ ), leading to a statistically significant difference in sBA between the TAK-625 and placebo groups (-117.28 [52.828]  $\mu\text{mol/L}$ ,  $p=0.0464$ ).

Similar results were observed in the ITT, with a significant increase in sBA from Week 18 to Week 22 in the RWD placebo group (LS mean [SE] increased by 95.21 [31.686]  $\mu\text{mol/L}$ ,  $p=0.0058$ ), but not in the RWD TAK-625 group (LS mean [SE] decreased or improved by 18.74 [35.251]  $\mu\text{mol/L}$ ,  $p=0.5995$ ), with a statistically significant difference in sBA between the TAK-625 and placebo groups (-113.95 [48.032]  $\mu\text{mol/L}$ ,  $p=0.0254$ ).

In the ITT, a statistically significant difference was observed in sBA from baseline to Week 18: mean change from baseline (SD) -87.73 (119.979)  $\mu\text{mol/L}$ ,  $p=0.0005$ .

##### 2. Observer-reported Itch Reported Outcome (ItchRO [Obs]): Weekly Average Morning Severity Score

Given the subjects' young age, an observer-reported outcome was used to measure subjects' pruritus symptoms as observed by their caregiver twice daily (once in the morning and once in the evening) on the ItchRO (Obs) instrument with scores ranging from 0 (none observed or reported) to 4 (very severe).

At Week 18, a statistically significant mean (SD) decrease (improvement) from baseline in ItchRO (Obs) weekly average morning severity scores were identified in the ITT (-1.704 [0.9114],  $p < 0.0001$ ) with similar reductions observed in the TAK-625 and placebo groups when analyzed separately.

At Week 22, a statistically significant increase (worsening) in mean (SD) change from Week 18 in ItchRO (Obs) scores was observed in the placebo group (1.712 [1.0054],  $p < 0.0001$ ), while no relevant change was observed in the TAK-625 group (0.201 [0.7551],  $p = 0.3754$ ).

Using an ANCOVA model, a significant increase in ItchRO (Obs) was observed in the RWD placebo group from Week 18 to Week 22 (LS mean [SE] increase of 1.700 [0.2031],  $p < 0.0001$ ), but not in the RWD TAK-625 group (LS mean [SE] increase of 0.217 [0.2345],  $p = 0.3639$ ), with a statistically significant difference in ItchRO (Obs) between the TAK-625 and placebo groups (-1.483 [0.3103],  $p < 0.0001$ ).

### **Safety Results:**

The incidence of treatment-emergent adverse events (TEAEs) was similar during the OL, ARW, and LTE phases, with the majority of subjects (86.2%-100%) experienced TEAEs. The most frequently reported TEAEs (>30% in at least 1 phase) were abdominal pain, pyrexia, diarrhea, nasopharyngitis, vomiting, cough, and pruritus. The incidence of abdominal pain was highest in the OL and LTE phases (12 subjects [38.7%] and 12 subjects [52.2%], respectively) and was lower in the ARW phase (6 subjects [20.7%]). During the RWD phase, subjects in the RWD TAK-625 group had a similar incidence of abdominal pain TEAEs compared with subjects in the RWD placebo group (1 subject [7.7%] and 1 subject [6.3%], respectively).

During the OL and LTE phases, 38.7% and 34.8% of subjects, respectively, experienced TEAEs potentially related to the study drug, while only 1 subject (3.4%) experienced such TEAEs during the ARW phase. During the RWD phase, subjects in the TAK-625 group had a lower incidence of TEAEs and TEAEs potentially related to the study drug (53.8% and 7.7%, respectively) compared with subjects in the placebo group (75% and 18.8%, respectively).

During the RWD phase, serious adverse events (SAEs) were reported for 1 subject each in the TAK-625 group and the placebo group. None of the SAEs were considered related to the study drug. A total of 6 subjects (2 subjects each in the OL, ARW, and LTE phases) experienced TEAEs leading to study drug discontinuation. No deaths occurred during the study.

#### **4.1.3.3 Study MRX-801 (Phase 2 Study)**

Currently, Study MRX-801, which is an open-label, multicenter, phase 2 study in pediatric subjects (<12 months of age) with ALGS or PFIC designed to evaluate the safety and tolerability of TAK-625, is ongoing. ALGS or PFIC subjects receive TAK-625 over a 13-week treatment period (core study period) that includes dose escalation and stable dosing. Stable dosing occurs at 400  $\mu$ g/kg once daily (once a day [QD]; for ALGS) and at 600  $\mu$ g/kg twice daily (twice daily [BID]; for PFIC), or at the highest tolerated dose. For subjects <1 month of age, the dose for both ALGS and PFIC is 75  $\mu$ g/kg QD for the duration of treatment below this age boundary.

The interim analyses were planned when at least 6 subjects had completed the 13-week core study period for each study cohort (ALGS and PFIC).

The following is a summary of the results for the ALGS cohort as of 4 May 2022:

A total of 8 subjects (<12 months of age [2-10 months]) with ALGS were enrolled in the study. All subjects successfully escalated to the proposed label dose of 400 µg/kg/day with the proposed single drug-escalation step. Overall, 7 subjects completed the 13-week core study period, and 1 subject discontinued during the 13-week core study period.

**Efficacy Results:**

Improvements in pruritus and sBA were observed, as indicated by decreases in Clinician Scratch Scale (CSS) scores and sBA levels over time with treatment with TAK-625.

The mean (SD) change in sBA from baseline at Week 13 was -88.91 (113.35) µmol/L. There were decreases in sBA from baseline to Week 3, 10, and 13.

The mean (SD) change from baseline to Week 13 for CSS score was -0.2 (1.91) and ranged from -3 to 3. The mean change from baseline for CSS score decreased from baseline to Week 6 and Week 13.

**Safety Results:**

TAK-625 was well tolerated. A total of 7 subjects (87.5%) experienced at least 1 TEAE, 2 subjects (25.0%) had a TEAE related to the study drug (both events were Grade 1 diarrhea), and 4 subjects (50.0%) had a Grade  $\geq 3$  TEAE, none of which were considered to be related to the study drug. The most frequent TEAEs were nasopharyngitis, abdominal pain, diarrhea, teething, and pyrexia. These events were in all cases self-limiting and resolved with no drug interruption or change in dose. Most TEAEs were Grade 1 in severity. Four subjects (50.0%) had 7 SAEs, none of which were considered to be related to the study drug. No TEAE led to study discontinuation or death.

Most subjects had fluctuations in liver chemistry (alanine aminotransferase [ALT], aspartate aminotransferase [AST]), and total bilirubin) from baseline to each time point; however, 4 subjects (50.0%) had a decrease from baseline in total bilirubin, indicating improvement over time. Most subjects maintained or had mild increases in lipid soluble vitamin (LSV) levels from baseline to each time point, consistent with standard-of-care vitamin supplementation administered to subjects with ALGS.

**4.2 Rationale for the Proposed Study**

TAK-625 has never been used in Japan, although Study LUM001-304 suggested that TAK-625 was safe and effective and the effect sustained in long-term period in subjects with ALGS. In this study, efficacy, safety, and PK profile of TAK-625 will be evaluated. This protocol was developed to confirm the similarity to Study LUM001-304 by comparing the results between Japanese data and overseas data. TAK-625 was well tolerated in subjects <12 months of age with ALGS with moderate to severe cholestasis in Study MRX-801. Given the clinical outcomes associated with PFIC and ALGS, including the negative impact on patients' and caregivers' quality of life and the fact that there are currently no or limited approved treatments for patients <12 months of age, there is a high unmet medical need for a novel treatment for these diseases.

Thus, patients <12 months of age will be enrolled as well as patients  $\geq$ 12 months of age in this study. Study MRX-801 was designed to enroll patients  $\geq$ 0 days of age with ALGS; however, from the age of onset of ALGS, it is assumed that the administration of TAK-625 would not be started before 1 month after birth. Therefore, patients  $\geq$ 1 month of age was planned to be enrolled in this study, in consideration of preventing the patients from being exposed to the amount of propylene glycol (PG) in TAK-625 over the maximum daily dose limit of PG specified in the guidance by the European Medicines Agency (EMA). The diagnostic criteria for ALGS in Japan are the same as those in overseas countries [6]. Regarding the current treatments for potential subjects for this study, who are without surgical treatment, there are only symptomatic medicines. Also, the overall process from diagnosis to treatment is not different in Japan and overseas. These support the rationale for comparison between data in Japanese subjects and data in non-Japanese subjects. However, since it is not feasible to include a placebo arm considering the extreme rarity of ALGS, the randomized, double-blind, placebo-controlled drug withdrawal period will not be used in this study. LSV deficiency will be monitored regularly for a long term as a potential adverse event (AE) based on the mechanism of action.

#### **4.3 Benefit/Risk Profile**

The proposed study is designed to evaluate the efficacy, safety, and PK profile of TAK-625 in Japanese patients with ALGS.

As previously stated in [Section 4.1.3](#), the safety and efficacy profile of TAK-625 in non-Japanese subjects with ALGS has been confirmed in Study LUM001-304, though TAK-625 has never been used in Japan. The long-term efficacy has been also confirmed in Study LUM001-304.

Based on clinical study data, diarrhoea, and abdominal pain have been classified as identified risk and transaminases increased has been classified as potential risk of TAK-625. The majority of reported severities of diarrhoea and abdominal pain in clinical studies were mild or moderate.

Therefore, TAK-625 has a positive benefit-risk profile in the treatment to ALGS.

### **5.0 STUDY OBJECTIVES AND ENDPOINTS**

#### **5.1 Objectives**

##### **5.1.1 Primary Objectives**

- To evaluate the efficacy and safety of TAK-625 in subjects with ALGS.

##### **5.1.2 Secondary Objectives**

- To evaluate the PK of TAK-625 in subjects with ALGS.
- To evaluate the efficacy of TAK-625 on biochemical markers of cholestasis and liver disease in subjects with ALGS.

## **5.2 Endpoints**

### **5.2.1 Primary Endpoint**

- The change from Week 18 to 22 of fasting sBA levels.

### **5.2.2 Secondary Endpoints**

#### *5.2.2.1 Key Secondary Endpoints*

- Change from baseline to Week 18:
  - Fasting sBA levels.
  - Pruritus as measured by ItchRO (Obs): weekly average severity (based on daily maximum of morning and evening severity scores).
  - Pruritus as measured by ItchRO (Obs): weekly average morning severity.
- Change from Week 18 to 22:
  - Pruritus as measured by ItchRO (Obs): weekly average severity (based on daily maximum of morning and evening severity scores).
  - Pruritus as measured by ItchRO (Obs): weekly average morning severity.

#### *5.2.2.2 Secondary Endpoints*


- Change from baseline to Week 18:
  - Pruritus as measured by Patient-reported Itch Reported Outcome (ItchRO [Pt]): weekly average severity (based on daily maximum of morning and evening severity scores).
  - Pruritus as measured by ItchRO (Pt): weekly average morning severity.
  - Liver enzymes (ALT and alkaline phosphatase [ALP]) and bilirubin (total and direct).
- Change from Week 18 to 22:
  - Pruritus as measured by ItchRO (Pt): weekly average severity (based on daily maximum of morning and evening severity scores).
  - Pruritus as measured by ItchRO (Pt): weekly average morning severity.
  - Liver enzymes (ALT and ALP) and bilirubin (total and direct).

### **5.2.3 Safety Endpoints**

- Incidence of AEs including SAEs, related to study drug, leading to study drug discontinuation, and AEs of clinical interest (AECIs).

AECIs include the following:

- LSV deficiency events.
- Liver parameter disruption.
- Change from baseline in clinical laboratory values (hematology, chemistry, urinalysis, and others), physical examination findings (including body weight, height, and body mass index [BMI]), vital signs, and electrocardiogram (ECG) parameters.



### **5.2.5 PK Endpoint**

- Plasma levels of TAK-625 at predose and approximately 4 hours after the morning dose at Week 12.
- Plasma levels of TAK-625 at predose (optional) and approximately 30 minutes after the morning dose at Week 18 (or any visit up to Week 28).

## **6.0 STUDY DESIGN AND DESCRIPTION**

### **6.1 Study Design**

This is a phase 3, multicenter, open-label, uncontrolled study to evaluate the efficacy and safety of TAK-625 in the treatment of Japanese subjects with ALGS.

#### Study Population:

The study population is defined as “Japanese patients with ALGS who are 1 month of age or older”.

#### Study Period (Screening, Treatment [Dose Escalation, Stable Dosing, and Follow-up Dosing], and Safety Follow-up Period):

This study consists of the screening period (up to 6 weeks prior to the study administration), 2-week dose escalation period (doses up to 400 µg/kg/day, QD, as tolerated), 46-week stable dosing period, and follow-up dosing period (until TAK-625 is approved or available in Japan commercially, or if the subject withdraws from the study, or if the investigator determines the subject’s discontinuation, or if the sponsor stops the program or development in this indication).

##### 1. Screening Period (Up to 6 Weeks prior to the Study Administration):

In the screening period, for subjects who do not have documentation of mutation related to ALGS (JAGGED-1 or NOTCH2), genetic testing may be performed, if necessary. The electronic diary (eDiary) for assessing pruritus with the Itch Reported Outcome (ItchRO) instrument will be dispensed and subjects and caregivers will undergo training during the screening visit.

##### 2. Dose Escalation Period (2 Weeks: Week 0 to 2):

In the 2-week dose escalation period, at the baseline visit (Week 0/Visit 2), subjects will be assessed to confirm continued study eligibility and undergo a physical examination including body weight, height, BMI, and vital signs, and have urine and blood samples taken for hematology, chemistry, fasting lipid panel, baseline levels of sBA, and other cholestasis biochemical markers. Compliance with ItchRO will be assessed. Study drug for Weeks 1 and 2 will be supplied at the baseline visit to eligible subjects. Subjects will receive the study drug, TAK-625, administered orally QD. The dose will be increased weekly over a 2-week period up to 400 µg/kg/day QD as follows: dose level 1, 200 µg/kg/day QD for 1 week; and dose level 2, 400 µg/kg/day QD for the remaining duration of the study. If an individual subject exhibits a treatment-emergent moderate or severe drug-related gastrointestinal (GI) toxicity with 400 µg/kg/day, study drug dose may be lowered to 200 µg/kg/day; later attempts to escalate the

dose are permitted during the dose escalation period. This decision should be made in consultation with the medical monitor. If further dose escalations fail during the dose escalation period, the subject will remain on 200 µg/kg/day for the remainder of the study. The dose should be taken at least 30 minutes prior to the first meal of the day. It is recommended that the dose should be taken approximately at the same time each day for the duration of the treatment period. Subjects will return to the clinic at Week 3 and follow-up phone calls will be made at Weeks 1 and 2.

**3. Stable Dosing Period (46 Weeks: Week 3 to 48):**

After the dose escalation period, each subject will continue dosing with study drug at the Week 3 dose level, which is either 200 or 400 µg/kg/day, in the stable dosing period. Subjects will visit the study site at Weeks 6, 12, 18, 22, 28, 38, and 48, and undergo physical examinations. Subject contacts (phone calls) will be conducted as appropriate throughout the stable dosing period. Subjects and caregivers will continue twice daily completion of their ItchRO throughout the period.

**4. Follow-up Dosing Period (after Week 48):**


In the follow-up dosing period, each subject will continue dosing with study drug at the Week 48 dose level, which is either 200 or 400 µg/kg/day. The safety evaluation will be performed in all the subjects every 12 weeks from Week 48 visit until TAK-625 is approved or available in Japan commercially, or if the subject withdraws from the study, or if the investigator determines the subject's discontinuation, or if the sponsor stops the program or development in this indication. Bile acids and ItchRO will be measured to evaluate the long-term effectiveness of TAK-625. For subjects discontinuing early, safety follow-up will be conducted.

**5. Safety Follow-up (after Final Visit/Early Termination [ET]):**

Subjects/caregivers will have a final safety follow-up subject contact (phone call) 7 days after the final study visit or ET visit (except for screen failure).

A schematic of the study design is included as [Figure 6.a](#) A schedule of assessments is listed in [Appendix A](#).

**Figure 6.a Schematic of Study Design**



DE=dose escalation; W=Week.

<sup>a</sup> Weekly dose escalation (2 weeks).

**Endpoint:**

Primary endpoint is the change from Week 18 to 22 of fasting sBA levels. Key secondary endpoints include the following: changes from baseline to Week 18 of fasting sBA levels, pruritus (weekly average severity) as measured by ItchRO (Obs), and pruritus (weekly average morning severity) as measured by ItchRO (Obs); and changes from Week 18 to 22 in fasting sBA levels, pruritus (weekly average severity) as measured by ItchRO (Obs), and pruritus (weekly average morning severity) as measured by ItchRO (Obs).

**Sample Size:**

In this study, approximately 5 subjects will be enrolled as targeted sample size.

**Sites and Regions:**

The study will be conducted in approximately 10 sites in Japan.

**Duration of Treatment:**

The study will be continued until TAK-625 is approved or available in Japan commercially, or if the subject withdraws from the study, or if the investigator determines the subject's discontinuation, or if the sponsor stops the program or development in this indication. A subject will be considered as having completed the study if the subject has not withdrawn early from the study for any reason prior to completing the end of treatment (EOT) visit.

If TAK-625 is approved for marketing by authorities during the study, the study can be shifted to a post-marketing study after the approval. In that case this protocol will continuously be used.

“Clinical Study” mentioned in the protocol will be read as “Post-marketing Study” as appropriate.

## **6.2 Justification for Study Design, Dose, and Endpoints**

TAK-625 has never been used in Japan, although Study LUM001-304 suggested that TAK-625 was safe and effective and the effect sustained in long-term period in subjects with ALGS. In this study, efficacy, safety, and PK profile of TAK-625 will be evaluated. This protocol was developed to confirm the similarity to Study LUM001-304 by comparing the results between Japanese data and overseas data.

### Justification for Study Population:

The study population is defined as Japanese patients with ALGS. Although the safety of TAK-625 was confirmed in subjects <12 months of age with ALGS with moderate to severe cholestasis enrolled in Study MRX-801, the lower age limit for enrollment in this study is set to be 1 month of age, in consideration of preventing the patients from being exposed to the amount of PG in TAK-625 over the maximum daily dose limit of PG specified in the guidance by the EMA.

The diagnostic criteria for ALGS in Japan are the same as those in overseas countries [6].

### Justification for Dose and Regimen of Study Drug:

The TAK-625 up to 400 µg/kg/day, orally QD dosing regimen was selected based on international phase 2 clinical trial of TAK-625 (Study LUM001-304).

TAK-625 is provided as an oral solution that is dosed on a weight basis. In phase 2 studies, TAK-625 has been administered to 119 pediatric subjects with cholestatic liver disease (33 with PFIC and 86 with ALGS; >12 months of age) at doses up to a maximum daily dose of 800 µg/kg/day. Dosing of 400 and 800 µg/kg/day (Study LUM001-304) and 280 and 560 µg/kg/day (Study LUM001-501) demonstrated a consistent safety profile. No maximum tolerated dose (MTD) has been determined at single doses up to 7000 µg/kg and multiple doses up to 1400 µg/kg/day. Furthermore, no dose-related safety findings have been identified to date. Effective and clinically relevant inhibition of the IBAT using TAK-625 has been demonstrated by durable reductions in sBA and pruritus levels in children with PFIC and ALGS ≥12 months of age on treatment for over 5 years. Improvements in pruritus and sBA were observed and the safety of TAK-625 was confirmed in infants <12 months of age with ALGS in the ongoing Study MRX-801, in which infants <12 months of age with ALGS or PFIC had been enrolled (the efficacy results in subjects <12 months of age with PFIC are not yet available). In a dose-finding phase 1 study (SHP625-101) conducted in overweight and obese adults, BID dosing (50 mg BID; 700 µg/kg BID equivalent) led to higher fBA excretion compared to 100 mg QD (1400 µg/kg QD equivalent). The safety profile was comparable across the tested dose range, with the exception of increased stool frequency at higher doses. In this study, the dose of TAK-625 up to 400 µg/kg/day, which is already approved by FDA will be evaluated in Japanese subjects with ALGS for efficacy and safety. Regarding dose escalation, the design was to escalate the dose of 14 µg/kg/day to 400 µg/kg/day by 1 week in 6 steps. However, the

FDA-approved commercial dose regimen is to escalate the dose of 200 µg/kg/day to 400 µg/kg/day by 1 week in 2 steps. A similar two-step dose escalation regimen was adopted in the Expanded Access Program (EAP) currently ongoing in the US, where 36 subjects have been requested by medical institutions to receive TAK-625 by the data cutoff on May 10, 2021. No additional safety concerns were observed in EAP. Therefore, it is considered that the reduction of the dose escalation step regimen to 2-step, from 6-step in Study LUM001-304, would not affect the safety. The time to the primary endpoint after reaching the therapeutic dose of 400 µg/kg/day was 12 weeks in Study LUM001-304 with 6-step escalation and 16 weeks in this study with 2-step escalation. However, since previous clinical studies suggested that the full treatment effects were already achieved as early as Week 12, it was considered that this 4-week difference will not affect the results of the primary endpoint.

#### Justification for Endpoints:

The endpoints are set to confirm the similarity to Study LUM001-304 by comparing the results between Japanese data and overseas data. The diagnostic criteria for ALGS in Japan are the same as those in overseas countries [6]. Regarding the current treatments for potential subjects for this study, who are without surgical treatment, there are only symptomatic medicines. Also, the overall process from diagnosis to treatment is not different in Japan and overseas. These support the rationale for comparison between data in Japanese subjects and data in non-Japanese subjects. However, since it is not feasible to include a placebo arm considering the extreme rarity of ALGS, the randomized, double-blind, placebo-controlled drug withdrawal period will not be used in this study.

### **6.3 Premature Termination or Suspension of Study or Study Site**

#### **6.3.1 Criteria for Premature Termination or Suspension of the Study**

The study will be completed as planned unless 1 or more of the following criteria are satisfied that require temporary suspension or ET of the study.

- New information or other evaluation regarding the safety or efficacy of the study drug that indicates a change in the known risk/benefit profile for the TAK-625, such that the risk/benefit is no longer acceptable for subjects participating in the study.
- Significant violation of Good Clinical Practice (GCP) that compromises the ability to achieve the primary study objectives or compromises subject safety.

#### **6.3.2 Criteria for Premature Termination or Suspension of Study Sites**

A study site may be terminated prematurely or suspended if the site (including the investigator) is found in significant violation of GCP, protocol, or contractual agreement, is unable to ensure adequate performance of the study, or as otherwise permitted by the contractual agreement.

### **6.3.3 Procedures for Premature Termination or Suspension of the Study or the Participation of Study Site(s)**

In the event that the sponsor, an institutional review board (IRB), or regulatory authority elects to terminate or suspend the study or the participation of a study site, a study-specific procedure for ET or suspension will be provided by the sponsor; the procedure will be followed by applicable study sites during the course of termination or study suspension.

### **6.3.4 Duration of an Individual Subject's Study Participation**

Subjects, including those who achieve a clinical response, may receive TAK-625 until TAK-625 is approved or available in Japan commercially, or if the subject withdraws from the study, or if the investigator determines the subject's discontinuation, or if the sponsor stops the program or development in this indication. Subjects will discontinue treatment if they have an unacceptable TAK-625-related toxicity.

Subjects will be followed for 7 days after the final study visit or ET visit to permit the detection of any delayed treatment-related AEs.

### **6.3.5 End of Study/Study Completion Definition and Planned Reporting**

#### End of Study:

The study will be continued until TAK-625 is approved or available in Japan commercially, or if the subject withdraws from the study, or if the investigator determines the subject's discontinuation, or if the sponsor stops the program or development in this indication. A subject will be considered as having completed the study if the subject has not withdrawn early from the study for any reason prior to completing the EOT visit.

If TAK-625 is approved for marketing by authorities during the study, the study can be shifted to a post-marketing study after the approval.

#### Study Completion:

The study completion date is defined as the date the final subject, across all sites, completes his or her final protocol-defined assessment. Note that this includes the follow-up visit or contact, whichever comes later (refer to [Section 9.3.6](#) for the defined follow-up period for this protocol) but not the long-term clinical follow-up of persistent safety findings.

Subjects who discontinue at any time during the treatment period will have a final safety follow-up subject contact (phone call) 7 days after the ET visit (see [Section 9.3.6](#)). Subjects who discontinue from the study for safety reasons are followed as long as clinically indicated or until no further improvement with an adverse outcome is expected.

#### Analysis Points:

Interim analysis will be performed at Weeks 22 and 48. Final clinical study report (CSR) will be prepared at the end of the study.

## 7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS

All entry criteria, including test results, need to be confirmed before first dose.

### 7.1 Inclusion Criteria

Subject eligibility is determined according to the following criteria before study entry:

1. The subject signs and dates an informed consent form/assent (as applicable) and any required privacy authorization prior to the initiation of any study procedures.  
If the subjects are under 18 years of age, the investigator is responsible for obtaining written informed consent not only from the under-aged subjects, but also from their legally acceptable representatives.
2. The subject is Japanese male or female with a body weight  $\geq 3.0$  kg and who is  $\geq 1$  month of age at the time of informed consent.

For subjects  $<12$  months of age, gestational age  $\geq 36$  weeks at birth. For subjects born with gestational age between 32 and 36 weeks, a postmenstrual age of  $\geq 36$  weeks is required. Postmenstrual age is defined as the time elapsed between the first day of the last menstrual period and birth plus the time elapsed after birth.

3. The subject is diagnosed with ALGS based on the diagnostic criteria outlined below.  
Major clinical criteria/features for ALGS include: cholestasis, consistent cardiac, renal, vascular, ocular, skeletal involvement, or characteristic “Alagille” facies.

ALGS Family History <sup>a</sup>	Paucity	JAGGED1 or NOTCH2 Mutation	Major Clinical Criteria Needed for Diagnosis
Present or Absent	Present	Identified <sup>b</sup>	Any or no features
None (proband)	Absent or unknown	Identified	1 or more features
None (proband)	Present	Not identified <sup>c</sup>	3 or more features
None (proband)	Absent or unknown	Not identified	4 or more features
Present	Absent or unknown	Identified	Any or no features
Present	Present	Not identified	1 or more features
Present	Absent or unknown	Not identified	2 or more features

<sup>a</sup> Family history=ALGS present in a first degree relative.

<sup>b</sup> Identified=JAGGED1 or NOTCH2 mutation identified in clinical laboratory.

<sup>c</sup> Not identified=Not identified on screening, or not screened for.

4. The subject has one or more of the following evidences of cholestasis:
  - a) Total sBA  $>3\times$  upper limit of the normal range (ULN) for age.
  - b) Direct bilirubin (conjugated)  $>1$  mg/dL.
  - c) LSV deficiency otherwise unexplainable.
  - d) Gamma-glutamyl transferase (GGT)  $>3\times$ ULN for age.

- e) Intractable pruritus explainable only by liver disease.
- 5. The subject is a male or female of non-childbearing potential. A male and non-pregnant, non-lactating female of childbearing potential who is sexually active must agree to use acceptable methods of contraception during the study and 30 days following the last dose of the study drug. A female of childbearing potential must have a negative pregnancy test result.

Definitions and highly effective methods of contraception are defined in [Section 9.1.13](#) and reporting responsibilities are defined in [Section 9.1.14](#).

- 6. The subject is expected to have a consistent caregiver(s) for the duration of the study.
- 7. The subject has an access to phone for scheduled calls from study site.
- 8. Both a caregiver and subject above the age of assent are capable of reading and understanding the questionnaires.
- 9. Caregivers (and age-appropriate subjects) must be willing and able to use an eDiary device during the study.
- 10. Caregivers (and age-appropriate subjects) must complete at least 10 eDiary reports (morning or evening) during each of 2 consecutive weeks of the screening period (maximum possible reports=14 per week), even if the subject is an adult (over 18 years old).

Average daily score >2 on the ItchRO questionnaire (maximum possible daily score of 4) for 2 consecutive weeks in the screening period, prior to dosing. A daily score is the higher of the scores for the morning and evening ItchRO. The average daily score is the sum of all daily scores divided by the number of days the ItchRO was completed. Since it is difficult to evaluate pruritus in infants, subjects <12 months of age at screening whose pruritus is unavoidably difficult to be evaluated are not necessarily required to meet the above score.

## 7.2 Exclusion Criteria

Any subject who meets any of the following criteria will not qualify for entry into the study:

- 1. The subject has chronic diarrhea requiring ongoing intravenous (IV) fluid or nutritional intervention.
- 2. The subject has a previous history of surgical interruption of the enterohepatic circulation.
- 3. The subject has a previous liver transplant.
- 4. The subject decompensated cirrhosis (ALT >15×ULN, international normalized ratio [INR] >1.5 [unresponsive to vitamin K therapy], albumin <3.0 g/dL, history or presence of clinically significant ascites, variceal hemorrhage, and/or encephalopathy).
- 5. The subject has a history or presence of other concomitant liver disease.

6. The subject has a history or presence of any other disease or condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs, including bile salt metabolism in the intestine (eg, inflammatory bowel disease).
7. The subject has a history or presence of gallstones or kidney stones.
8. The subject has a possible malignant liver mass in imaging, including screening ultrasound.
9. The subject has a history of human immunodeficiency virus (HIV) infection.
10. The subject has cancers, except for in situ carcinoma, or cancers treated at least 5 years prior to screening with no evidence of recurrence.
11. The subject has a recent medical history or current status that suggests that the subject may be unable to complete the study.
12. The subject is any female who is pregnant or lactating or who is planning to become pregnant during the study period.
13. The subject has a known history of alcohol or substance abuse.
14. The subject has received bile acid/lipid binding resins or IBAT inhibitors within 28 days prior to screening and throughout the trial (refer to [Section 7.3](#)).
15. The subject who has received sodium phenylbutyrate for less than 6 months at the initiation of screening (refer to [Section 7.3](#) and [Section 7.5.1.2](#)).
16. The subject has a known hypersensitivity to TAK-625 or any of its components.
17. The subject participated in another clinical study within 28 days or 5 half-lives (whichever is longer) prior to screening.
18. The subject has a history of nonadherence to medical regimens, unreliability, mental instability, or incompetence that could compromise the validity of informed consent or lead to nonadherence with the study protocol based upon investigator judgment.
19. The subject has any other conditions or abnormalities which, in the opinion of the investigator or medical monitor, may compromise the safety of the subject, or interfere with the subject participating in or completing the study.
20. The subject is judged by the investigator as being ineligible for any other reason.

### **7.3 Excluded Medications**

The following medications are prohibited during TAK-625 treatment and within the provided timeframe prior to screening.

<b>Prior Therapy</b>	<b>Time Restriction</b>
Bile acid/Lipid binding resins	Within 28 days prior to screening and throughout the trial.
IBAT inhibitors	Within 28 days prior to screening and throughout the trial.
Sodium phenylbutyrate	If the subject has received sodium phenylbutyrate for less than 6 months at the initiation of screening, the subject cannot be enrolled. (If the subject has received sodium phenylbutyrate for 6 months or more at the initiation of screening, the medication is permitted; however, the dose of sodium phenylbutyrate should not be changed during the study [refer to <a href="#">Section 7.5.1.2</a> ].)

IBAT=ileal bile acid transporter.

Subjects must be instructed not to take any medications including over-the-counter products, without first consulting with the investigator.

#### **7.3.1 Justification of Excluded Medications**

- Bile acids/Lipid binding resins: Since bile acids/lipid binding resins have been used for treatment of pruritus, these medications are excluded to avoid any influence on the efficacy results of TAK-625.
- IBAT inhibitors: Since the mechanism of action of IBAT inhibitors is similar to that of TAK-625, these medications are excluded to avoid any influence on the safety and efficacy results of TAK-625.
- Sodium phenylbutyrate: If the subject has received sodium phenylbutyrate for less than 6 months at the initiation of screening, the subject cannot be enrolled; since sodium phenylbutyrate has been shown to influence pruritus due to cholestatic diseases, the medication is excluded to avoid any influence on efficacy results of TAK-625. Meanwhile, if the subject has received sodium phenylbutyrate for 6 months or more at the initiation of screening, the medication is permitted, because the drug's effect is considered to have reached a plateau.

### **7.4 Excluded Procedures and Treatments**

The subject with a history of surgical interruption of the enterohepatic circulation or liver transplant should not be included in the study.

#### **7.4.1 Justification of Excluded Procedures and Treatments**

- Surgical interruption of the enterohepatic circulation: The surgical interruption of the enterohepatic circulation is excluded from the study due to its significant impact on bile acid homeostasis.

- Liver transplant: The liver transplant is excluded from the study since this is considered as a curable treatment for ALGS.

## 7.5 On Study Restrictions

### 7.5.1 Concomitant Medications, Procedures, and Treatments

A subject should not be instructed to discontinue use of any medication or treatment to participate in this study until informed consent (or assent as applicable) has been obtained.

Concomitant treatment refers to all treatment, including concomitant therapies, as well as herbal treatments, vitamins, behavioral treatment, non-pharmacological treatment, such as psychotherapy, taken between the dates of the first dose of study drug and the end of the subject's participation in the study. Concomitant treatment information must be recorded in the subject's source document.

#### 7.5.1.1 *Prohibited Concomitant Medications, Procedures, and Treatments*

The prohibited concomitant medications, procedures, and treatments are described in [Section 7.3](#) and [Section 7.4](#).

#### 7.5.1.2 *Permitted Concomitant Medications, Procedures, and Treatments*

The following medications to treat cholestasis/pruritus are allowed during the study if the subject has been on a stable dosing regimen (ie, same dose and frequency in the 30 days prior to the screening visit [Visit 1]) and will continue this dosing regimen throughout study participation. The investigator must contact the medical monitor to discuss any changes to and introduction of concomitant treatments to treat cholestasis/pruritus not listed here that could impact the outcome of the study. Dose adaptations to body weight changes are allowed.

- Ursodeoxycholic, cholic acid, chenodeoxycholic acid, or dehydrocholic acid.
- Antihistamines.
- Nalfurafine.
- Phenobarbital.
- Rifampicin.
- Naloxone.

Administration of sodium phenylbutyrate is permitted only under the conditions below. However, the dose of sodium phenylbutyrate should not be changed during the study; temporary dose adjustments for safety concerns or dose adaptations to body weight changes are permitted at the discretion of the investigator.

1. Stable dosing for 6 months or more at the initiation of screening; temporary dose adjustments for safety concerns or dose adaptations to body weight changes are permitted at the discretion of the investigator.
2. Assessed to be in a stable condition (no more improvement will be expected) by the investigator.

#### **7.5.1.3 LSVs**

The investigators must ensure that subjects receive LSV supplements, as needed, for the duration of the study.

#### **7.5.2 Diet, Fluid, and Activity Control**

- The dose should be taken at least 30 minutes prior to the first meal of the day. It is recommended that the dose should be taken approximately at the same time each day throughout the study. The last meal time prior to blood sampling will be recorded on the source document and electronic case report form (eCRF) at each visit.

For infants with a body weight <5 kg, at-home dilution will be required (refer to [Section 8.1.3](#)).

For PK plasma samples at approximately 30 minutes ( $\pm$ 15 minutes) after morning dose at Week 18 (or any visit up to Week 28), the PK sampling should be conducted before breakfast.

- Blood samples for the analysis of cholestasis biomarkers, lipid panel, and LSV should be drawn prior to administration of vitamin supplementation and as much as possible after 4 hours or more of the last food or formula (water intake is permitted if necessary but not recommended). For subjects <12 months of age, samples should be taken before feeding, after 2 hours or more of the last food or formula, and before administration of vitamin supplementation, when possible (water intake, excluding milk, is allowed when required) (refer to [Appendix A](#)).

#### **7.6 Criteria for Discontinuation or Withdrawal of a Subject**

The primary reason for discontinuation or withdrawal of the subject from the study or study drug should be recorded in the eCRF using the following categories. For screen failure subjects, refer to [Section 9.1.21](#).

1. AEs.
2. Protocol deviation. The discovery after the first dose of study drug that the subject did not meet protocol entry criteria or did not adhere to protocol requirements, and continued participation poses an unacceptable risk to the subject's health.

3. Lost to follow-up. The subject did not attend visits and attempts to contact the subject were unsuccessful. Attempts to contact the subject must be documented in the subject's source documents.
4. Withdrawal by subject. The subject (or subject's legally acceptable representative) wishes to withdraw from the study. The reason for withdrawal, if provided, should be recorded in the eCRF.

Note: All attempts should be made to determine the underlying reason for the withdrawal and, where possible, the primary underlying reason should be recorded (ie, withdrawal due to an AE should not be recorded in the "voluntary withdrawal" category. Similarly, lack of efficacy should not be recorded in the "voluntary withdrawal" category).

5. Study termination. The sponsor, IRB, or regulatory agency terminates the study.
6. Pregnancy. The subject is found to be pregnant.

Note: If the subject is found to be pregnant, the subject must be withdrawn immediately. The procedure is described in [Section 9.1.14](#).

7. Lack of efficacy. The investigator has determined that the subject is not benefiting from study treatment; and continued participation would pose an unacceptable risk to the subject.
8. Other.

Note: The specific reasons should be recorded in the "specify" field of the eCRF.

If subjects discontinue from the study due to disease progression and require rescue therapy with either surgical interruption of the enterohepatic circulation or listing for liver transplant, both the reason for discontinuation and outcome (ie, PEBD, cholecystostomy tube, ileal exclusion, liver transplant, or listed for liver transplant) should be recorded in the subject's source document. If known, the date of the future scheduled procedure should also be recorded. The information regarding surgical interruption of the enterohepatic circulation, liver transplant, or listing for transplant will be collected in the eCRF at the time the subject completes/early terminates from the study (EOT/ET) until the completion of the safety follow-up period.

## 7.7 Procedures for Discontinuation or Withdrawal of a Subject

The investigator may discontinue a subject's study participation at any time during the study when the subject meets the study termination criteria described in [Section 7.6](#). In addition, a subject may discontinue his or her participation without giving a reason at any time during the study. Should a subject's participation be discontinued, the primary criterion for termination must be recorded by the investigator. In addition, efforts should be made to perform all procedures scheduled for the ET visit.

## **8.0 CLINICAL STUDY MATERIAL MANAGEMENT**

This section contains information regarding all medications and materials provided directly by the sponsor, and/or sourced by other means, that are required by the study protocol, including important sections describing the management of study material.

### **8.1 Study Drug and Materials**

#### **8.1.1 Dosage Form, Manufacturing, Packaging, and Labeling**

In this protocol, the term study drug refers to any of the drugs defined in [Section 8.1.1.1](#).

For details and the handling of the study drug, refer to the “Investigator’s Brochure (IB)” and “Pharmacy Manual”.

##### **8.1.1.1 Study Drug**

The doses described in this study protocol are for maralixibat chloride (not free base) but are written as “TAK-625”. For example, 400 µg/kg of maralixibat chloride is equivalent to 380 µg/kg of TAK 625 free base but is referred to as 400 µg/kg of TAK-625 in this study protocol (the latest TAK-625 IB).

The study drug of this study is TAK-625 (formerly maralixibat, SHP625, LUM001), which will be provided as an oral solution form (10 mg/mL) along with either 0.5, 1.0, or 3.0-mL sized oral dosing dispensers. Equipment for at-home dilution will also be supplied where required.

TAK-625 are presented in 30-mL volumes packaged in an amber colored polyethylene terephthalate (PET) bottles equipped with a child resistant cap and require refrigerated storage conditions (2°C to 8°C).

One of the excipients in the TAK-625 oral solution is PG; in order to limit subject exposure to PG, a specific strength of oral solution will be prescribed to a given subject based on body weight and target dose. The dosing plan will limit PG exposure to  $\leq 26$  mg/kg/day and, at the same time, will provide reasonable (not too high or too low) dosing volumes to ensure accurate dosing.

Further details are described separately in a “Pharmacy Manual”.

##### **8.1.1.2 Packaging**

Study drug will be provided with primary packaging and labelling only (no secondary packaging/secondary labeling). Study drug is packaged in the following labeled containers:

- Ready-to-use oral solution of TAK-625 10 mg/mL.

The sponsor or designee will provide 0.5, 1.0, and 3.0 mL sized oral dosing dispensers to study sites. Bottle adapters and equipment for at-home dilution will also be supplied where required. Changes to sponsor-supplied packaging may not occur without full agreement in advance by the sponsor.

#### **8.1.1.3 Labeling**

All study drug is labeled according to Japan requirements.

Japanese label is used for TAK-625 oral solution in Japan. Further details are described separately in a “Pharmacy Manual”.

#### **8.1.2 Storage**

Study drug must be kept in an appropriate, limited-access, secure place until it is used or returned to the sponsor or designee for destruction. TAK-625 must be stored at refrigerated storage conditions (2°C to 8°C). A daily temperature log of the drug storage area must be maintained every working day. Further details are described separately in a “Pharmacy Manual”.

#### **8.1.3 Dose and Regimen**

**Route of Administration:** oral

**Dose Regimen:**

Subjects will receive TAK-625 (up to 400 µg/kg/day), orally QD.

The dose should be taken at least 30 minutes prior to the first meal of the day. It is recommended that the dose should be taken approximately at the same time each day throughout the study. For infants with a body weight <5 kg, at-home dilution will be required. This will include a 5-fold dilution of assigned TAK-625 with a predefined quantity of water. Refer to the “Pharmacy Manual” for a dosing table with the dilution scheme.

Subjects will take the first dose of study drug at the baseline visit (Week 0/Visit 2) after all of the exam procedures were performed under the supervision of the investigator or trained staff.

The interval between administration of study drug and any concomitant treatment should not change during the study.

The dose may be down-titrated throughout the study, at the investigator’s discretion and in consultation with the medical monitor, for subjects experiencing intolerance (eg, GI symptoms such as diarrhea, abdominal pain, cramping) to a given dose. Subjects who were down-titrated after the stable dosing period may be rechallenged after discussion with the medical monitor. However, it is preferable to administer the study drug at a stable dose as much as possible until Week 22.

**1. Dose Escalation Period (2 weeks: Week 0 to 2):**

The dose will be increased weekly over a 2-week period up to 400 µg/kg/day QD as follows:

The dose escalation period will consist of the following weekly steps:

Dose level 1: 200 µg/kg/day QD for 1 week

Dose level 2: 400 µg/kg/day QD for the remaining duration of the study

GI intolerance, as evidenced by diarrhea/loose stools, abdominal pain/cramping, and nausea, is expected to be the most frequent manifestation of a lack of tolerability to study drug. If an individual subject exhibits a treatment-emergent moderate or severe drug-related GI toxicity with 400 µg/kg/day, study drug dose may be lowered to 200 µg/kg/day; later attempts to escalate the dose are permitted during the dose escalation period. This decision should be made in consultation with the medical monitor. If further dose escalations fail during the dose escalation period, the subject will remain on 200 µg/kg/day for the remainder of the study. A requirement for IV fluids as treatment for diarrhea will lead to discontinuation of study drug.

The investigators should also review study drug compliance during the dose escalation period to ensure that subjects have adequate exposure to study drug to assess safety and tolerability. Any compliance concerns should be discussed with the medical monitor.

**2. Stable Dosing Period (46 Weeks: Week 3 to 48):**

After the dose escalation period, each subject will continue dosing with study drug at the Week 3 dose level, which is either 200 or 400 µg/kg/day, in the stable dosing period.

**3. Follow-up Dosing Period (after Week 48):**

In the follow-up dosing period, each subject will continue dosing with study drug at the Week 48 dose level, which is either 200 or 400 µg/kg/day. The safety evaluation will be performed in all the subjects every 12 weeks from Week 48 visit until TAK-625 is approved or available in Japan commercially, or if the subject withdraws from the study, or if the investigator determines the subject's discontinuation, or if the sponsor stops the program or development in this indication.

**8.1.4      Stopping Criteria of Dosing**

Subject dosing must be suspended until the retest results are available. Refer to [Sections 10.4.3, 10.4.5, 10.4.6, and 10.4.7](#).

**8.1.5      Overdose and Medication Error**

An overdose is defined as a known deliberate or accidental administration of study drug, to or by a study subject, at a dose above that which is assigned to that individual subject according to the study protocol.

A medication error is defined as an error made in prescribing, dispensing, administration, and/or use of a study medication. For studies, medication errors are reportable to the sponsor only as defined below.

Cases of subjects missing doses of the study medication are not considered reportable as medication errors. The administration and/or use of the unassigned or expired study medication is/are always reportable as a medication error.

All cases of overdose or medication error (with or without associated AEs) will be documented. Cases of overdose or medication error without manifested signs or symptoms are not considered

AEs. AEs associated with an overdose or a medication error will be documented on AE eCRFs according to [Section 10.0](#).

SAEs associated with overdose or medication error should be reported according to the procedure outlined in [Section 10.2.2](#).

In the event of drug overdose or medication error, the subject should be treated by the investigator based on symptoms.

## **8.2 Study Compliance**

Subject compliance with study procedures and treatment compliance will be assessed at each treatment visit by the site staff.

During the dose escalation period, subject compliance will be reviewed as part of the dose escalation assessment. Any concerns with compliance should be discussed with the medical monitor.

Procedures outlined in [Section 9.3.4](#) should be followed for any subject who is discontinued early from the study.

## **8.3 Study Drug Assignment and Dispensing Procedures**

Subjects will receive treatment according to the study schedule.

The investigator or designee will utilize Interactive Response Technology (IRT) at screening to register the subject into the study and obtain an enrollment number/subject number to identify the subject throughout the study. During this contact, the investigator or designee will provide the necessary subject-identifying information, including the subject identification (ID) number. The medication ID number of the study drug to be dispensed will then be provided by the IRT as well as at subsequent visits. If sponsor-supplied drug is lost or damaged, the site can request a replacement from IRT. Refer to IRT manual provided separately. The medication ID number will be entered onto the eCRF.

A study manual/user manual with specific functions and instructions for the IRT will be provided to the site, and site personnel will receive training. Please refer to the study manual/user manual for additional details regarding the IRT.

## **8.4 Accountability and Destruction of Sponsor-Supplied Drugs**

Drug supplies will be counted and reconciled at the site before being returned to the sponsor or designee.

The on-site pharmacist (site designee) will receive the pharmacy manual created by the sponsor, according to which the site designee will appropriately manage the sponsor-supplied drug. The investigator will also receive those procedures from the sponsor. The procedures include those for ensuring appropriate receipt, handling, storage, management, dispensation of the

sponsor-supplied drug, and collection of medications from the subject as well as return of them to the sponsor or destruction of them.

The on-site pharmacist (site designee) will immediately return unused study drugs to the sponsor after the study is closed at the study site.

Refer to “Pharmacy Manual” for detailed and additional instructions.

## **9.0 STUDY PLAN**

### **9.1 Study Procedures**

The following sections describe the study procedures and data to be collected. For each procedure, subjects are to be assessed by the same investigator or site personnel whenever possible. The Schedule of Study Procedures is located in [Appendix A](#).

#### **9.1.1 Informed Consent Procedure**

The requirements of the informed consent are described in [Section 15.2](#).

Informed consent must be obtained prior to the subject entering into the study, and before any protocol-directed procedures are performed.

A unique subject ID number (subject number) will be assigned to each subject at the time that informed consent is obtained. This subject number will be used throughout the study.

If the subjects are under 18 years of age, the investigator is responsible for obtaining written informed consent not only from the under-aged subjects, but also from their legally acceptable representatives.

#### **9.1.2 Eligibility Assessment**

The investigator should confirm the subject’s eligibility at the screening and prior the first administration (Visit 1 and Visit 2). Subjects who meet eligibility criteria after completion of all screening assessments will enter the dose escalation period.

The screening period will last at a minimum 2 weeks to confirm the average daily score  $>2$  on the ItchRO (Obs) and completion of at least 10 eDiary reports, and will allow for the evaluation of each subject’s eligibility for inclusion into the study. Since it is difficult to evaluate pruritus in infants, subjects  $<12$  months of age at screening whose pruritus is unavoidably difficult to be evaluated are not necessarily required to meet the above score. The requirements of Itch Reported Outcome (ItchRO™) are described in [Section 9.1.7.1.1](#).

### **9.1.3 Demographics, Medical History, Disease History, and Medication History/Prior Treatment Procedure**

#### Demographics:

Subject demographic information including sex, date of birth, and race will be collected at the screening visit (Visit 1). Variance in pediatric age-related reference ranges is significant, and the date of birth is required to ensure correct interpretation of the laboratory report.

#### Medical History:

Medical history to be obtained will include determining whether the subject has any significant conditions or diseases relevant to the disease under study that resolved within 1 year prior to signing of informed consent. Ongoing conditions are considered concurrent medical conditions (see [Section 9.1.10](#)).

#### Disease History:

During the screening, the investigator will record ALGS disease history.

#### Medication History/Prior Treatment:

Medication history/prior treatment information to be obtained includes any medication/treatment relevant to eligibility criteria and efficacy/safety evaluation stopped at or within 3 months prior to signing of informed consent.

### **9.1.4 Physical Examination Procedure**

Abnormalities identified at the screening visit (Visit 1) and the baseline (Week 0/Visit 2) will be documented in the subject's source documents. Significant changes after the screening visit (Visit 1) or the baseline (Week 0/Visit 2) should be assessed as pretreatment events. Refer to [Section 10.0](#) for additional details.

Physical examination assessments should also include specific assessments for signs of hepatomegaly, splenomegaly, edema, ascites, jaundice, and scleral icterus.

### **9.1.5 Weight, Height, and BMI**

Weight will be assessed at the screening visit (Visit 1), the baseline (Week 0/Visit 2), and at the site visits during the treatment period, and recorded to the nearest 0.1 kg, using a balance or electronic scale (children who can stand on their own, generally  $\geq 2$  years of age) or infant scale (generally  $< 2$  years of age).

Height will be collected at the screening visit (Visit 1), the baseline (Week 0/Visit 2), and at all site visits during the treatment period. Height will be measured by trained site staff in children who can stand on their own (generally  $\geq 2$  years of age) or not (generally  $< 2$  years of age) using a stadiometer or headboard, respectively, via 2 independent measurements, recorded to the nearest 0.1 cm (and a third measurement if values differ by  $> 0.5$  cm). The same stadiometer should be

used for all study visit measurements. The detailed procedure will be provided in the “Height and Weight Guidance”.

BMI is calculated using metric units with the formula provided below: Height is recorded in centimeters without decimal places. Weight is collected in kilograms (kg) with 1 decimal place. BMI should be derived as:

$$\text{BMI} = \text{weight (kg)} / \text{height (m)}^2$$

### **9.1.6 Vital Sign Procedure**

Vital signs include blood pressure, heart rate, temperature, and respiration rate. Blood pressure should be determined by cuff using the same method, the same arm, and the same position, following 5 minutes of rest throughout the study. Any deviations of vital signs from the screening visit (Visit 1) or the baseline (Week 0/Visit 2) vital signs that are deemed clinically significant in the opinion of the investigator are to be recorded as an AE.

When vital signs are scheduled at the same time as blood draws, the blood draw will take priority and vital signs will be obtained within 0.5 hour before or after the scheduled blood draw.

### **9.1.7 Primary Efficacy Measurement**

#### **9.1.7.1 eDiary**

Subjects and caregivers will be trained on the use of the eDiary during the screening visit (Visit 1). Pruritus will be assessed and recorded twice daily, via ItchRO™, beginning with the day after the screening visit (Visit 1) and every day throughout the duration of the study, as described in [Appendix A](#).

Throughout the duration of the study, subjects/caregivers will be required to submit twice daily (morning and evening) assessments using the eDiary.

##### **9.1.7.1.1 Itch Reported Outcome (ItchRO™)**

Pruritus will be assessed using the Itch caregiver/patient reported outcome (PRO) measure (ItchRO™) administered as a twice daily eDiary as described in [Appendix D](#). Caregivers for all subjects will complete the Observer instrument: ItchRO (Obs). The ItchRO (Obs) should be completed by the same caregiver for consistency, whenever possible. The caregivers should assess subject’s pruritus and record it, even if the subject is an adult (over 18 years old).

The ItchRO (Obs) eligibility must be determined after a minimum of 2 weeks of ItchRO (Obs) twice daily diary entry. If the subject does not meet eligibility after 2 weeks, ItchRO (Obs) eligibility should be re-assessed at Week 3, and also at Week 4 if eligibility is not met at Week 3. A maximum of 3 attempts can be made to determine ItchRO (Obs) eligibility during the screening period.

Only subjects  $\geq 9$  years of age at the screening visit (Visit 1) will complete the patient instrument: ItchRO (Pt). If a subject turns 9 years of age at any point after the screening visit (Visit 1), they

will not complete the ItchRO (Pt). Due to the expected low number of subjects old enough to rate ItchRO (Pt), this measure will only be analyzed as an exploratory outcome.

#### ItchRO (Obs)<sup>TM</sup>

The severity of pruritus will be measured by the completion of the first question in the ItchRO (Obs) (how severe were your child's itch-related symptoms). The frequency of pruritus will be measured by completion of the third question in the ItchRO (Obs) (how much of the time was your child rubbing or scratching). Caregivers will rate the severity and frequency of pruritus using 5 choices to describe their pruritus condition.

#### ItchRO (Pt)<sup>TM</sup>

The severity of pruritus will be measured by the completion of the first question in the ItchRO (Pt) (how itchy did you feel). The frequency of pruritus will be measured by completion of the third question in the ItchRO (Pt) (how much of last night/today did feeling itchy make you rub or scratch). Subjects will rate the severity and frequency of pruritus using 5 choices to describe their pruritus condition.


#### *9.1.7.2 Serum Bile Acids and Other Cholestasis Biomarkers*


Blood samples will be collected as described in [Appendix A](#) and to measure levels of cholestasis biomarkers including total sBA, sBA subspecies, 7 $\alpha$ C4, FGF-19\*, and autotaxin\* as well as liver-related parameters. Subjects  $\geq$ 12 months of age are encouraged to fast at least 4 hours prior to collection (water intake is permitted if necessary but not recommended). Subjects <12 months of age are encouraged to fast at least 2 hours prior to collection (water intake, excluding milk, is allowed when required).

\* FGF-19 and autotaxin are not mandatory, if the subjects are too small to collect enough amount of blood.

Total sBA and sBA subspecies will be quantified with liquid chromatography-mass spectrometry (LC-MS) methodology for assessments. In addition, screening total sBA will be assessed with an enzymatic assay for inclusion criteria evaluation. 7 $\alpha$ C4, a key intermediate in the pathway for bile acid synthesis from cholesterol, will be determined by a validated liquid chromatograph-tandem mass spectrometer (LC-MS/MS) method.

#### *9.1.8 Other Efficacy Measurement*





### **9.1.9 Documentation of Concomitant Medications**

Concomitant medication is any drug given in addition to the study drug. These may be prescribed by a physician or obtained by the subject over the counter. Concomitant medication is not provided by the sponsor. At each study visit, subjects will be asked whether they have taken any medication other than the study drug (used from signing of informed consent through the end of the study), and all medication including vitamin supplements, over-the-counter medications, and oral herbal preparations, must be recorded in the eCRF.

The investigators must ensure that subjects receive LSV supplements, as needed, for the duration of the study.

### **9.1.10 Documentation of Concurrent Medical Conditions (Complication)**

Concurrent medical conditions are those significant ongoing conditions or diseases that are present at signing of informed consent. This includes clinically significant laboratory, ECG, or physical examination abnormalities noted at screening/baseline examination, according to the judgment of the investigator. The condition (ie, diagnosis) should be described.

### **9.1.11 Procedures for Clinical Laboratory Samples**

Clinical laboratory evaluations will be performed according to the central laboratory manual. If possible, reference ranges are to be supplied by the laboratory and will be used to assess the clinical laboratory data for clinical significance and out-of-range pathological changes. The investigator must assess out-of-range clinical laboratory values for clinical significance, indicating if the value(s) is/are not clinically significant or clinically significant. Abnormal clinical laboratory values, which are unexpected or not explained by the subject's clinical condition, may, at the discretion of the investigator or sponsor, be repeated as soon as possible until confirmed, explained, or resolved.

Clinical laboratory assessments will be performed as listed in [Table 9.a](#).

The sBA (LC-MS) and PK samples must be examined at central laboratory, in all subjects. In addition, screening total sBA (enzymatic assay) for inclusion criteria evaluation must be examined at central laboratory, in all subjects. The samples for chemistry panel, LSV, cholestasis biomarkers, lipid panel, complete blood count (CBC), coagulation,  $\alpha$ -fetoprotein (AFP), and serum storage samples could be examined at study sites, if the subjects are too small to collect enough amount of blood for the central laboratory, depending on the investigator's decision. For each subject, the blood samples should be examined at the same laboratory throughout the study once the laboratory is determined by the investigator, as much as possible.

A serum storage sample will be collected as a back-up sample in case re-analysis is needed.

According to the Ethical Considerations for Clinical Trials on Medicinal Products Conducted with the Paediatric Population, the volume of blood drawn from a subject should not exceed 3% of the total blood volume during a period of 4 weeks and should not exceed 1% at any single time [\[8\]](#). Should the volume of blood required for a single visit or a 30-day period exceed the

maximum allowable amount, the investigator will draw blood in the priority order listed in [Appendix B](#) until the maximum amount has been reached. Laboratory draws missing due to the maximum allowable amount being reached will not be considered protocol deviations. Further instructions will be provided in the “Guidance on Maximum Volume of Blood Draws”.

When the laboratory data has not been collected electronically, the investigator or designee is responsible for transcribing laboratory results to the eCRF. The investigator will maintain a copy of the laboratory accreditation and the reference ranges for the laboratory used.

Unscheduled assessments (eg, laboratory values) are not required to be collected in the eCRF except for those that are directly relevant to the monitoring of an AE/SAE; collection of other values may be requested by the sponsor.

Anion gap and osmolar gap as well as corrected sodium,  $\alpha$ -tocopherol/total lipids ratio, retinol/retinol binding protein (RBP) molar ratio [REDACTED] will be calculated.

Property of Takeda: For non-commercial use only and subject to the applicable Terms of Use

**Table 9.a Clinical Laboratory Tests**

<b>Hematology (CBC with Differential)</b>	<b>Chemistry</b>	<b>Urinalysis</b>
Hematocrit	Albumin	pH
Hemoglobin	ALP	Specific gravity
MCV, MCH, MCHC	Amylase	Protein
Red blood cells	ALT (SGPT)	Glucose
Platelets	AST (SGOT)	Ketones
White blood cells	Bicarbonate	Bilirubin
WBC Differential (% and absolute)	Bilirubin, direct (conjugated)	Occult blood and cells
Neutrophils	TSB	Nitrite
Eosinophils	BUN	Urobilinogen
Basophils	Calcium	Leukocyte esterase
Lymphocytes	Chloride	Microscopic examination
Monocytes	Creatinine	Oxalate
	GGT	Urinary creatinine
	Glucose	
	Lipase	
	Phosphate	
	Potassium	
	Sodium	
	Total protein	
	Total sBA (enzymatic assay)	
	Uric Acid	
	Measured serum Osmolality	
<b>Other:</b>		
<b>Coagulation</b>		
aPTT (sec)	<b>Lipid Panel</b>	<b>TAK-625 Levels</b>
INR	Total cholesterol	TAK-625 in plasma
PT (sec)	LDL-C (direct)	
	HDL-C	
	TG	
<b>Cholestasis Biomarkers</b>		
	sBA (LC-MS)	
	sBA subspecies	
	7 $\alpha$ C4	
	FGF-19 <sup>a</sup>	
	Autotaxin <sup>a</sup>	
<b>Lipid Soluble Vitamins</b>		
	25-hydroxy vitamin D	
	Retinol	
	RBP <sup>b</sup>	
	$\alpha$ -Tocopherol	
<b>Urine</b>		
	$\beta$ -hCG (for pregnancy)	

AFP= $\alpha$ -fetoprotein; ALP=alkaline phosphatase; ALT=alanine aminotransferase; aPTT=activated partial thromboplastin time; AST=aspartate aminotransferase; 7 $\alpha$ C4=7 $\alpha$ -hydroxy-4-cholesten-3-one;  $\beta$ -hCG= $\beta$ -human chorionic gonadotropin; BUN=blood urea nitrogen; CBC=complete blood count; FGF-19=fibroblast growth factor 19; GGT=gamma-glutamyl transferase; HCC=hepatocellular carcinoma; HDL-C=high density lipoprotein-cholesterol; INR=international normalized ratio; LC-MS=liquid chromatography-mass spectrometry; LDL-C=low density lipoprotein-cholesterol; LSV=lipid soluble vitamin; MCH=mean corpuscular hemoglobin; MCHC=mean corpuscular hemoglobin concentration; MCV=mean corpuscular volume; PT=prothrombin time; RBP=retinol binding protein; sBA=serum bile acid; SGOT=serum glutamic-oxaloacetic transaminase; SGPT=serum glutamic-pyruvic transaminase; TG=triglycerides; TSB=total serum bilirubin; WBC=white blood cell.

a) FGF-19 and autotaxin are not mandatory, if the subjects are too small to collect enough amount of blood.

b) Performed when clinically indicated or in case of low retinol levels for subjects <12 months of age.

The central/local laboratory will perform laboratory tests for hematology, chemistry, urinalysis, and others. The results of laboratory tests will be returned to the investigator, who is responsible for reviewing and filing these results.

### **9.1.12    Pregnancy Test**

A urine pregnancy test is performed on all female subjects of childbearing potential prior to dispensing study drug at study visits as outlined in [Appendix A](#), or if pregnancy is suspected or on withdrawal of the subject from the study.

### **9.1.13    Contraception and Pregnancy Avoidance Procedure**

#### *9.1.13.1    Male Subjects and Their Female Partners*

From signing of informed consent, throughout the duration of the study, and for 30 days after the last dose of study drug, nonsterilized\*\* male subjects who are sexually active with a female partner of childbearing potential\* must use barrier contraception (eg, condom with or without spermicidal cream or jelly). In addition, they must be advised not to donate sperm during this period. Females of childbearing potential who are partners of male subjects are also advised to use additional contraception as shown in the list containing highly effective/effective contraception below (from the list in [Section 9.1.13.3](#)).

#### *9.1.13.2    Female Subjects and Their Male Partners*

From signing of informed consent, throughout the duration of the study, and for 30 days after last dose of study drug, female subjects of childbearing potential\* who are sexually active with a nonsterilized male partner\*\* must use a highly effective/effective method of contraception (from the list in [Section 9.1.13.3](#)).

In addition, they must be advised not to donate ova during this period.

#### *9.1.13.3    Definitions and Procedures for Contraception and Pregnancy Avoidance*

*The following definitions apply for contraception and pregnancy avoidance procedures.*

\* A woman is considered a woman of childbearing potential (WOCBP), ie, fertile, following menarche and until becoming postmenopausal unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range (FSH >40 IU/L) may be used to confirm a postmenopausal state in younger women (eg, those <45-year-old) or women who are not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.

\*\* Sterilized males should be at least 1 year post-bilateral vasectomy and have confirmed that they have obtained documentation of the absence of sperm in the ejaculate or have had bilateral orchidectomy.

*The following procedures apply for contraception and pregnancy avoidance.*

1. Acceptable and available methods of contraception in Japan are shown in this section. A male subject who is non-sterilized and sexually active with a female partner of childbearing potential must use male condom. Females of childbearing potential who are partners of male subjects are also advised to, or a female subject of childbearing potential who is sexually active with a nonsterilized male partner must use the method of contraception below.
  - Intrauterine devices (IUDs).
  - Bilateral tubal interruption/tubal ligation.
  - A Male partner who is the only partner of the subject and was postvasectomy and have confirmed that they have obtained documentation of the absence of sperm in the ejaculate.
  - Progestin/Estrogen mixed preparation for inhibition of ovulation initiated at least 3 months prior to the first dose of study drug OR combined with a barrier method (male condom, female condom† or diaphragm†) if for shorter duration until she has been on contraceptive for 3 months.
2. Unacceptable methods of contraception are:
  - Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods).
  - Spermicides† only.
  - Withdrawal.
  - No method at all.
  - Use of female† and male condoms together.
  - Cap†/diaphragm†/sponge† without spermicide and without condom.
  - Sexual abstinence is NOT an acceptable method of contraception.
3. Subjects will be provided with information on highly effective/effective methods of contraception as part of the subject informed consent process and will be asked to sign a consent form stating that they understand the requirements for avoidance of pregnancy, donation of ova, and sperm donation during the course of the study.
4. During the course of the study, regular urine  $\beta$ -human chorionic gonadotropin ( $\beta$ -hCG) pregnancy tests will be performed only for females of childbearing potential and all subjects

Property of Takeda. All rights reserved. Subject to the applicable Terms of Use.

(male and female) will receive continued guidance with respect to the avoidance of pregnancy and sperm donation as part of the study procedures. Such guidance should include a reminder of the following:

- a) Contraceptive requirements of the study.
- b) Reasons for use of barrier methods (ie, condom) in males with pregnant partners.
- c) Assessment of subject compliance through questions such as:
  - i. Have you used the contraception consistently and correctly since the last visit?
  - ii. Have you forgotten to use contraception since the last visit?
  - iii. Are your menses late (even in women with irregular or infrequent menstrual cycles a pregnancy test must be performed if the answer is “yes”).
  - iv. Is there a chance you could be pregnant?
5. In addition to a negative urine  $\beta$ -hCG pregnancy test at screening, female subjects of childbearing potential must also have confirmed menses in the month before first dosing (no delayed menses), a negative urine  $\beta$ -hCG pregnancy test at Visit 1 and Visit 2.

#### *9.1.13.4 General Guidance with Respect to the Avoidance of Pregnancy*

From signing of informed consent and throughout the duration of the study and for 30 days after the last dose, female subjects of childbearing potential (ie, nonsterilized, premenopausal female subjects) who are sexually active must use acceptable methods of contraception. Also from signing of informed consent, throughout the duration of the study, and for 30 days after last dose, nonsterilized male subjects who are sexually active with a female partner of childbearing potential must use contraception. Such subjects will be provided with information on acceptable methods of contraception as part of the subject informed consent process and will be asked to sign a consent form stating that they understand the requirements for avoidance of pregnancy during the course of the study. During the course of the study, regular urine  $\beta$ -hCG pregnancy tests will be performed, and subjects will receive continued guidance with respect to avoiding pregnancy as part of the study procedures ([Appendix A](#)).

In addition to a negative urine  $\beta$ -hCG pregnancy test at screening period, subjects also must have a negative urine  $\beta$ -hCG pregnancy test on the day of the first dose of study drug (predose), before to receiving any dose of study drug.

In addition, male subjects must be advised not to donate sperm from signing of informed consent to 30 days after the last dose of study drug.

#### **9.1.14 Pregnancy**

If any subject is found to be pregnant during the study, she should be withdrawn and any sponsor-supplied drug should be immediately discontinued. In addition, any pregnancies in the

partner of a male subject during the study or for 30 days after the last dose, should also be recorded following authorization from the subject's partner.

If the pregnancy occurs during administration of study drug or within 30 days of the last dose of study drug, the pregnancy should be reported immediately, using a pregnancy notification form, to the contact listed in the annex.

If the female subject and/or female partner of a male subject agrees to the primary care physician being informed, the investigator should notify the primary care physician that the female subject/female partner of the subject was participating in a clinical study at the time she became pregnant and provide details of the study drug the subject received.

All pregnancies, including female partners of male subjects, in subjects on study drug will be followed up to final outcome, using the pregnancy form. Pregnancies will remain blinded to the study team. The outcome, including any premature termination, must be reported to the sponsor. An evaluation after the birth of the child will also be conducted.

#### **9.1.15 ECG Procedure**

The following parameters will be collected: heart rate, RR interval, PR interval, QRS duration, uncorrected QT interval, rhythm (sinus or specify other rhythm), ECG normal or abnormal (if abnormal specify abnormality).

QT interval corrected using both Bazett's and Fridericia's formula (QTcB and QTcF) will be derived from data collected in the eCRF.

ECGs should be recorded in the supine position, if possible after at least 10 minutes rest to ensure a stable baseline. A standard 12-lead ECG will be performed at the screening (Visit 1) and other visits as outlined in [Appendix A](#). ECGs will be recorded locally in source documents and results captured in the eCRF.

#### **9.1.16 Ultrasound Liver Imaging**

An abdominal ultrasound will be performed at the screening (Visit 1) and other visits as outlined in [Appendix A](#) to determine the presence of any liver mass. A screening ultrasound is not required if the results of an ultrasound or liver magnetic resonance imaging (MRI) completed in the last 6 months are available, and the clinical status of the subject has not changed significantly since the time of the test.

#### **9.1.17 AE Collection**

At each study visit and subject contact, subjects or their caregivers will be questioned in a general way to ascertain if AEs have occurred since the previous visit (eg, "Have you had any health problems since your last visit?"). AEs will be collected from the time informed consent is signed (refer to [Section 10.0](#)).

### 9.1.18 Other Safety Evaluation

Safety will be evaluated based on the occurrence of all AEs, SAEs, AECIs, physical examination findings, vital signs (blood pressure, heart rate, temperature, and respiration rate), clinical laboratory parameters (hematology, chemistry, urinalysis, and others).

AECIs include the following:

- LSV deficiency events.
- Liver parameter disruption.

Safety laboratory tests to be performed at site visits and processed by a central laboratory. However, these could be processed at sites, if the subjects are too small to collect enough amount of blood for the central laboratory, depending on the investigator's decision. The investigator should assess out-of-range clinical laboratory values for clinical significance, indicating if the value(s) is/are not clinically significant or clinically significant. Additional evaluations may be performed at the discretion of the investigator in consultation with the medical monitor or designee.

**Stopping Rule Guidance:** Subject dosing must be suspended until the retest results are available. If any of the stopping criteria described in [Section 10.4.3](#) and [Section 10.4.6](#) is confirmed, the investigator in consultation with the medical monitor (or appropriately qualified designee) will permanently discontinue the subject from further treatment with study drug.

### 9.1.19 Genetic Testing (ALGS Genotype)

JAGGED1 and NOTCH2 mutations can be predictive of ALGS. For ALGS subjects who meet clinical diagnostic criteria for ALGS (see [Section 7.1](#)) but do not have documentation of a JAGGED1 or NOTCH2 mutation, the clinical diagnosis of ALGS may be confirmed by genotyping, if necessary. Subjects for whom prior genotyping was performed may need to have an optional repeat analysis performed if the original information collected at screening was insufficient for complete documentation of the diagnosis of ALGS including the type of mutation recorded in the source document. For those subjects for which the type of the mutation cannot be documented, genetic testing may be performed and the results recorded on the source document and eCRF, if necessary.

### 9.1.20 PK Sample Collection and Analysis

#### 9.1.20.1 Collection of Blood for PK Sampling

Blood samples (one sample per scheduled time) for serum TAK-625 concentration will be collected according to the Schedule of Study Procedures ([Appendix A](#)).

Plasma PK samples at predose and approximately 4 hours ( $\pm 30$  minutes) after morning dose at Week 12 and at predose and approximately 30 minutes ( $\pm 15$  minutes) after morning dose at Week 18 will be collected. If sample collections at Week 18 are difficult, PK samples can be collected at any visit up to Week 28. Additionally, predose at Week 18 is optional. Postdose PK

samples should be collected in preference to predose PK samples, if the subjects are too small to collect enough amount of blood.

The actual dates and times of PK sample collection, the last dose of study drug before the predose PK sample collection and the postdose PK sample collection, and the last meal of each PK sample collection will be recorded on the source document and eCRF.

Instructions for collecting, processing, and shipping of PK samples are provided in the laboratory manual.

#### **9.1.21 Documentation of Screen Failure**

The investigators must account for all subjects who sign informed consent.

If the subject is withdrawn at the screening visit, the investigator should complete the eCRF. The IRT should be contacted as a notification of screen failure.

The primary reason for screen failure is recorded in the eCRF using the following categories:

- AE.
- Screen failure (Did not meet inclusion criteria or did meet exclusion criteria <specify reason>).
- Protocol deviation.
- Lost to follow-up.
- Pregnancy.
- Withdrawal by subject <specify reason>.
- Study termination.
- Other <specify reason>.

Subject ID numbers assigned to subjects who fail screening should not be reused.

#### **9.1.22 Documentation of Study Entrance**

Only subjects who meet all of the inclusion criteria and none of the exclusion criteria are eligible for entrance into the dose escalation period.

If the subject is found to be not eligible for treatment phase, the investigator should record the primary reason for failure on the applicable eCRF.

### **9.2 Monitoring Subject Treatment Compliance**

The study drug administration will be recorded in the eCRF/eDiary.

When administration of a study drug was inappropriately conducted, the dosage and the reasons will be recorded in the eCRF/eDiary.

Subjects will be required to bring study drug containers/unused study drugs to each dispensing site visit. All study drugs administered to the subject will be recorded on the eCRFs.

During the dose escalation period, subject compliance will be reviewed as part of the dose escalation assessment. Any concerns with compliance should be discussed with the medical monitor.

Procedures outlined in [Section 9.3.4](#) should be followed for any subject who is discontinued early from the study.

### **9.3 Schedule of Observations and Procedures**

The schedule for all study-related procedures for all evaluations is shown in [Appendix A](#). Assessments should be completed at the designated visit/time point(s).

Prior to performing any study-related procedures (including those related to screening), the investigator or designee must obtain written informed consent (or assent as applicable) from the subject (as per local requirements). For information about informed consent process see [Section 15.2](#).

Enrollment numbers /subject numbers are assigned to all subjects as they consent to take part in the study.

Within each site, the subject number is assigned to subjects according to the sequence of presentation for study participation.

The investigator will utilize IRT at screening to register the subject into the study and obtain an enrollment number/subject number to identify the subject throughout the study.

#### **9.3.1 Screening Period**

The screening period starts when informed consent (or assent as applicable) is signed. The duration of the screening period is up to 6 weeks during which all procedures listed for the screening visit (Visit 1) in [Appendix A](#) must be completed.

The screening period will last at a minimum 2 weeks to confirm the average daily score  $>2$  on the ItchRO (Obs) score and completion of at least 10 eDiary reports, and will allow for the evaluation of each subject's eligibility for inclusion into the study. Since it is difficult to evaluate pruritus in infants, subjects  $<12$  months of age at screening whose pruritus is unavoidably difficult to be evaluated are not necessarily required to meet the above score. If the subject does not meet eligibility after 2 weeks, ItchRO (Obs) eligibility should be re-assessed at Week 3, and also at Week 4 if eligibility is not met at Week 3. A maximum of 3 attempts can be made to determine ItchRO (Obs) eligibility during the screening period and will allow for the evaluation of each subject's eligibility for inclusion into the study. The requirements of ItchRO™ are described in [Section 9.1.7.1.1](#).

Subjects who meet eligibility criteria after completion of all screening assessments will enter the dose escalation period. This period should not commence until all screening assessments required to confirm eligibility for administering of study drug.

If the subject does not meet eligibility criteria following completion of screening assessments, the investigator or designee will document the subject as a screen failure in the IRT. A screen failure is a subject who has given informed consent and failed to meet the inclusion and/or met at least 1 of the exclusion criteria and has not been administered study drug.

In exceptional cases, subjects who initially fail to meet all eligibility criteria may be re-screened at a later timepoint, after consultation with the medical monitor.

Screen failure subject numbers cannot be reassigned to other subjects.

A 5-day visit window will be permitted in the case the 42-day screening period needs to be extended. This window will allow for blood sample retesting at the investigator's discretion.

Procedures to be completed at the screening visit include:

- Informed consent/assent.
- Eligibility assessment based on inclusion/exclusion criteria.
- Demographics, medical history, disease history (including complication), and medication/treatment history.
- Physical examination, vital signs, weight, height, and BMI.
- 12-lead ECG.
- Liver ultrasound.
- Pregnancy test (urine, for females of childbearing potential).
- Confirming ALGS genotype based on a genotyping (for subjects who do not have documentation of mutation related with ALGS), if necessary.
- eDiary supply and instructions.
- [REDACTED]
- [REDACTED]
- Screening clinical laboratory tests (blood).
- AE assessment.
- Concomitant medications (including confirmation of the need to administer LSV supplements).
- Access IRT to obtain subject number.

### **9.3.2 Dose Escalation Period**

Subjects who continue to meet all eligibility criteria will receive TAK-625 as described in [Appendix A](#) at the baseline visit (Week 0/Visit 2).

The dose escalation period will comprise of 2 weeks. All assessments and procedures listed for visits and subject contacts (phone calls) from Week 0 to 2 in [Appendix A](#) should be completed during this period.

#### *9.3.2.1 Visit in the Dose Escalation Period*

During the dose escalation period, a  $\pm 2$ -day visit window will be permitted, unless otherwise specified. Visit dates and acceptable windows are calculated from the baseline visit (Week 0/Visit 2).

Procedures to be completed in the dose escalation visit (Week 0) include:

- Eligibility assessment based on inclusion/exclusion criteria.
- Physical examination, vital signs, weight, height, and BMI.
- 12-lead ECG.
- Pregnancy test (urine, for females of childbearing potential).
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- Clinical laboratory tests (blood).
- Clinical laboratory tests (urine).
- Blood collection for serum storage.
- eDiary review.
- Study drug compliance review.
- Study drug supply and return.
- AE assessment.
- Concomitant medications (including confirmation of the need to administer LSV supplements).

### 9.3.2.2 *Phone Calls in the Dose Escalation Period*

During the dose escalation period, subjects/caregivers will receive subject contacts (phone calls) on Weeks 1 and 2 to review the use of concomitant treatments, study drug compliances, and AEs as outlined in [Appendix A](#).

For subject contacts (phone calls) of Weeks 1 and 2, a  $\pm 2$ -day window will be permitted. Contact dates and acceptable windows are calculated from the baseline visit (Week 0/Visit 2).

Procedures to be completed in the subject contacts (phone calls) include:

- Study drug compliance review.
- AE assessment.
- Concomitant medications (including confirmation of the need to administer LSV supplements).

### 9.3.3 **Stable Dosing Period**

After the dose escalation period, each subject will continue dosing with study drug at the Week 3 dose level, which is either 200 or 400  $\mu\text{g}/\text{kg}/\text{day}$ , in the stable dosing period.

The stable dosing period will comprise of 46 weeks. All assessments and procedures listed for visits and subject contacts (phone calls) from Week 3 to 48 in [Appendix A](#) should be completed during this period.

#### 9.3.3.1 *Visits in the Stable Dosing Period*

During the stable dosing period, for Weeks 3 and 6, a  $\pm 2$ -day visit window will be permitted. From Week 12 to 22 and Week 28 to 48, a  $\pm 5$ -day visit window will be permitted. Visit dates and acceptable windows are calculated from the baseline visit (Week 0/Visit 2).

Procedures to be completed in the stable dosing visit include:

- Physical examination, vital signs, weight, height, and BMI.
- 12-lead ECG (at Weeks 12, 28, and 48).
- Liver ultrasound (at Week 48).
- Pregnancy test (urine, for females of childbearing potential).
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- Clinical laboratory tests (blood).

- Clinical laboratory tests (urine).
- Blood collection for PK (at Weeks 12 and 18).
- Blood collection for serum storage.
- eDiary review.
- Study drug compliance review.
- Study drug supply and return.
- AE assessment.
- Concomitant medications (including confirmation of the need to administer LSV supplements).

#### **9.3.3.2      *Phone Calls the Stable Dosing Period***

During the stable dosing period, subjects/caregivers will receive subject contacts (phone calls) on Weeks 4, 5, 9, 20, 23, 24, 25, 26, 27, 33, and 43 to review the use of concomitant treatments, study drug compliances, and AEs as outlined in [Appendix A](#).

For subject contacts (phone calls) at Weeks 4 and 5, and from Week 23 to 27, a  $\pm 2$ -day window will be permitted. At Weeks 9, 20, 33, and 43, a  $\pm 5$ -day visit window will be permitted. Contact dates and acceptable windows are calculated from the baseline visit (Week 0/Visit 2).

Procedures to be completed in the subject contacts (phone calls) include:

- Study drug compliance review.
- AE assessment.
- Concomitant medications (including confirmation of the need to administer LSV supplements).

#### **9.3.4      ET**

Subjects will return to the study site for ET and the procedures and assessments outlined in [Appendix A](#) will be performed.

If study drug is permanently discontinued early, regardless of the reason, the subject will be discontinued from the study (refer to [Section 7.6](#)), and the evaluations listed for the ET are to be performed. The subject should undergo the ET assessments at the visit during which study drug was discontinued, or the subject should be scheduled for an additional ET visit as soon as possible, if study drug was discontinued between visits.

Subjects who discontinue prematurely at any time during the treatment period will have a final safety follow-up subject contact (phone call) 7 days after the ET visit.

- Physical examination, vital signs, weight, height, and BMI.

- 12-lead ECG.
- Liver ultrasound.
- Pregnancy test (urine, for females of childbearing potential).
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- Clinical laboratory tests (blood).
- Clinical laboratory tests (urine).
- Blood collection for serum storage.
- eDiary review.
- Study drug compliance review.
- AE assessment.
- Concomitant medications (including confirmation of the need to administer LSV supplements).

### **9.3.5 Follow-up Dosing Period**

Additionally, in the follow-up dosing period, each subject will continue dosing with study drug. The safety evaluation will be performed every 12 weeks from Week 48 visit until TAK-625 is approved or available in Japan commercially, or if the subject withdraws from the study, or if the investigator determines the subject's discontinuation, or if the sponsor stops the program or development in this indication.

Procedures to be completed in the follow-up dosing visit include:

- Physical examination, vital signs, weight, height, and BMI.
- 12-lead ECG.
- Liver ultrasound.
- Pregnancy test (urine, for females of childbearing potential).
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]

- Clinical laboratory tests (blood).
- Clinical laboratory tests (urine).
- Blood collection for serum storage.
- eDiary review.
- Study drug supply and return.
- Study drug compliance review.
- AE assessment.
- Concomitant medications (including confirmation of the need to administer LSV supplements).

### **9.3.6 Safety Follow-up**

The safety follow-up period for this protocol is 7 days from the final study visit or ET visit. Subjects/caregivers will have a final safety follow-up subject contact (phone call) 7 days after the final study visit or ET visit (except for screen failure).

Subjects who discontinue at any time during the treatment period will have a final safety follow-up subject contact (phone call) 7 days after the ET visit.

Subjects who discontinue from the study for safety reasons are also followed-up as long as clinically indicated or until no further improvement with an adverse outcome is expected. All AEs and SAEs that are not resolved at the time of this contact will be followed to closure by the site (see [Section 10.0](#)).

### **9.3.7 Post Study Care**

The study will be continued until TAK-625 is approved or available in Japan commercially, or if the subject withdraws from the study, or if the investigator determines the subject's discontinuation, or if the sponsor stops the program or development in this indication. A subject will be considered as having completed the study if the subject has not withdrawn early from the study for any reason prior to completing the EOT visit.

If TAK-625 is approved for marketing by authorities during the study, the study can be shifted to a post-marketing study after the approval.

### **9.3.8 Alternative Approaches to Study Procedures and Data Collection Due to Coronavirus Disease 2019**

In unavoidable circumstances that impact the study site's ability to conduct study procedures according to the Schedule of Study Procedures ([Appendix A](#)), in particular during the coronavirus disease 2019 (COVID-19) pandemic, contingency measures may be implemented. The following information provides guidance regarding changes to the study procedures that could be implemented for study subjects or study sites that are affected by the COVID-19 public

health emergency. This guidance is aligned with the current guidance from global health authorities on the conduct of clinical studies during the COVID-19 pandemic.

As the COVID-19 pandemic may peak in different regions at different times, and as restrictions implemented by local laws and recommendations may vary, any decision on procedural changes should be made on a case-by-case basis by the principal investigator in consultation with the sponsor or designee, while maintaining subject safety and confidentiality as the priority.

The principal investigator should also notify the local IRB, as appropriate, of any deviation for temporary use of alternative methods for conducting subject visits (eg, video conferencing, telephone visits) in the event of restrictive measures due to the COVID-19 pandemic, per local requirements.

Procedural changes due to COVID-19 may include the following:

- No routine COVID-19 testing is required during the study unless the subject has signs or symptoms of COVID-19-related disease or COVID-19 pneumonia in the opinion of the investigator, or the subject has been identified by national or local public health authority as a close contact of a probable or confirmed case of COVID-19. The decision to have the subject tested for COVID-19 is left to the subject and the investigator unless required by the health authority.
- Subjects who discontinued from screening due to COVID-19-related factors but were otherwise qualified to participate in the study may be re-screened if the sponsor or designee agrees.
- All attempts should be made to perform the assessments with the subject present at the site using the visit windows. Exceptions may be granted for alternative approaches to study procedures and data collection through approval by the sponsor or designee. Such instances must be documented in the study records and may include the following:
  - Sites impacted by the COVID-19 pandemic must contact the sponsor or designee to discuss individual subject and site circumstances to obtain approval for use of alternative approaches to study procedures and data collection.
  - Sites may seek approval from the medical monitor to continue subjects in the study despite departure from the Schedule of Study Procedures. Principal investigators are expected to evaluate the impact to the safety of the study subjects and site personnel for subjects to continue. In evaluating such requests, the sponsor or designee will give the highest priority to the safety and welfare of the subjects. Subjects must be willing and able to continue taking study medication and remain compliant with the protocol.
- Informed Consent Procedure: If necessary, informed consent from a potential or current study subject's parent or guardian may be obtained via verbal consent when these individuals are unable to travel to the site. Informed consent forms will be signed once the subject and his/her parent, or guardian can return in person to the study site.

- Visits: All visits must be done with the subject present at the study site.
  - Protocol Deviations: Any deviations from the protocol-specified procedures due to COVID-19 will be recorded as related to COVID-19.
  - Visit Window Extension: Sites may seek approval from the sponsor or designee to extend a visit window in order to conduct an on-site visit. Assessments that cannot be completed during the protocol-specified window will be recorded as a protocol deviation, and such deviations will be recorded in the study records as related to COVID-19.
  - Local laboratory test may be applicable for assessing clinical chemistry and hematology
- EOT/ET visit: The EOT/ET visit should be performed with the subject present at the study site. Sites may seek approval from the sponsor or designee to extend a visit window in order to conduct an on-site visit. If the visit cannot be conducted on-site within the visit window granted by the sponsor or designee, sites may conduct EOT/ET visit procedures remotely as is feasible, including using local laboratories for assessment of biochemistry, hematology, and urinalysis (as specified in [Appendix A](#)). Assessments that cannot be completed during the protocol-specified window will be recorded as a protocol deviation, and such deviations will be recorded in the study records as related to COVID-19.
- When a physical examination or other in-person procedure is needed in response to an AE, the subject should be evaluated in-person at the site per protocol if possible. If the subject cannot visit the site due to COVID-19, the site should contact the medical monitor.
- Discontinuation or Withdrawal from the Study or Study Medication: If a subject chooses to withdraw from the study or study medication due to personal concerns related to the COVID-19 pandemic (other than a COVID-19-related AE), this must be specified as the reason for subject withdrawal in the eCRF.
- Allow transfer of study subjects to study sites away from risk zones or closer to their home to sites already participating in the study or new ones.
- For subjects who are impacted by certain factors, any alternative approaches to study procedures (ie, procedures not conducted per the Schedule of Study Procedures) due to the COVID-19 pandemic must be documented in the study records as related to COVID-19. Data collected using alternative methods may be handled differently in the final data analyses. This will be documented in the statistical analysis plan (SAP).

#### 9.4 Biological Sample Retention and Destruction

The additional blood samples collected for this study will be stored at its affiliated companies for up to 15 years from when the study results are reported or if less, the maximum period permitted under applicable law or until consent is withdrawn.

## **10.0 AEs**

### **10.1 Definitions**

#### **10.1.1 Pretreatment Events**

A pretreatment event is defined as any untoward medical occurrence in a clinical investigation subject who has signed informed consent to participate in a study but before administration of any study drug; it does not necessarily have to have a causal relationship with study participation.

#### **10.1.2 AEs**

An AE is defined as any untoward medical occurrence in a clinical investigation subject administered a drug; it does not necessarily have to have a causal relationship with this treatment.

An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory value), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug. This includes any newly occurring event or a previous condition that has increased in severity or frequency since the administration of study drug.

#### **10.1.3 Additional Points to Consider for AEs**

An untoward finding generally may:

- Indicate a new diagnosis or unexpected worsening of a pre-existing condition. (Intermittent events for pre-existing conditions or underlying disease should not be considered AEs.)
- Necessitate therapeutic intervention.
- Require an invasive diagnostic procedure.
- Require discontinuation or a change in dose of study drug or a concomitant medication.
- Be considered unfavorable by the investigator for any reason.

Diagnoses vs signs and symptoms:

- Each event should be recorded to represent a single diagnosis. Accompanying signs (including abnormal laboratory values or ECG findings) or symptoms should NOT be recorded as additional AEs. If a diagnosis is unknown, sign(s) or symptom(s) should be recorded appropriately as an AE(s).

Laboratory values and ECG findings:

- Changes in laboratory values or ECG findings are only considered to be AEs if they are judged to be clinically significant (ie, if some action or intervention is required or if the investigator judges the change to be beyond the range of normal physiologic fluctuation). A

laboratory or ECG retest and/or continued monitoring of an abnormal value or finding are not considered an intervention. In addition, repeated or additional noninvasive testing for verification, evaluation or monitoring of an abnormality is not considered an intervention.

- If abnormal laboratory values or ECG findings are the result of pathology for which there is an overall diagnosis (eg, increased creatinine in renal failure), the diagnosis only should be reported appropriately as an AE.

Pre-existing conditions:

- Pre-existing conditions (present at the time of signing of informed consent) are considered concurrent medical conditions and should NOT be recorded as AEs. Baseline evaluations (eg, laboratory tests, ECG, X-rays etc.) should NOT be recorded as AEs unless related to study procedures. However, if the subject experiences a worsening or complication of such a concurrent medical condition, the worsening or complication should be recorded appropriately as an AE. The investigators should ensure that the event term recorded captures the change in the condition (eg, “worsening of...”).
- If a subject has a pre-existing episodic concurrent medical condition (eg, asthma, epilepsy) any occurrence of an episode should only be captured as an AE if the condition becomes more frequent, serious, or severe in nature. The investigators should ensure that the AE term recorded captures the change in the condition from baseline (eg, “worsening of...”).
- If a subject has a degenerative concurrent medical condition (eg, cataracts, rheumatoid arthritis), worsening of the condition should only be recorded as an AE if occurring to a greater extent to that which would be expected. The investigators should ensure that the AE term recorded captures the change in the condition (eg, “worsening of...”).

Worsening of AEs:

- If the subject experiences a worsening or complication of an AE after any change in study drug, the worsening or complication should be recorded as a new AE. The investigators should ensure that the AE term recorded captures the change in the condition (eg, “worsening of...”).

Changes in intensity of AEs:

- If the subject experiences changes in intensity of an AE, the event should be captured once with the maximum intensity recorded.

Preplanned procedures (surgeries or interventions):

- Preplanned procedures (surgeries or therapies) that were scheduled prior to signing of informed consent are not considered AEs. However, if a preplanned procedure is performed early (eg, as an emergency) due to a worsening of the pre-existing condition, the worsening of the condition should be recorded as an AE. Complications resulting from any planned surgery should be reported as AEs.

Elective surgeries or procedures:

- Elective procedures performed where there is no change in the subject's medical condition should not be recorded as AEs but should be documented in the subject's source documents. Complications resulting from an elective surgery should be reported as AEs.

Insufficient clinical response (lack of efficacy):

- Insufficient clinical response, efficacy, or pharmacologic action, should NOT be recorded as an AE. The investigator must make the distinction between exacerbation of pre-existing illness and lack of therapeutic efficacy.

Overdose and medication error:

- Cases of overdose or medication error with any medication without manifested side effects are NOT considered AEs, but instead will be documented as overdose or medication error separately. Any manifested side effects will be considered AEs and will be recorded on the AE page of the eCRF.

#### **10.1.4 SAEs**

An SAE is defined as any untoward medical occurrence that at any dose:

1. Results in DEATH.
2. Is LIFE THREATENING.
  - The term "life threatening" refers to an event in which the subject was at risk of death at the time of the event; it does not refer to an event that hypothetically might have caused death if it were more severe.
3. Requires inpatient HOSPITALIZATION or prolongation of existing hospitalization.
4. Results in persistent or significant DISABILITY/INCAPACITY.
5. Leads to a CONGENITAL ANOMALY/BIRTH DEFECT.
6. Is an IMPORTANT MEDICAL EVENT that satisfies any of the following:
  - May require intervention to prevent items 1 through 5 above.
  - May expose the subject to danger, even though the event is not immediately life threatening or fatal or does not result in hospitalization.

#### **10.1.5 AECIs**

An AECI (serious or non-serious) is one of scientific and medical concern specific to the compound or program, for which ongoing monitoring may be appropriate. Such events may require further investigation in order to characterize and understand them.

In this study AECIs include the following:

- LSV deficiency events.
- Liver parameter disruption.

#### **10.1.6    Intensity of AEs**

The different categories of intensity (severity) are characterized as follows:

Mild:                    The event is transient and easily tolerated by the subject.  
Moderate:               The event causes the subject discomfort and interrupts the subject's usual activities.  
Severe:                 The event causes considerable interference with the subject's usual activities.

#### **10.1.7    Causality of AEs**

The relationship of each AE to study drug(s) will be assessed using the following categories:

Related:                An AE that follows a reasonable temporal sequence from administration of a drug (including the course after withdrawal of the drug), or for which possible involvement of the drug cannot be ruled out, although factors other than the drug, such as underlying diseases, complications, concomitant medications, and concurrent treatments, may also be responsible.  
Not Related:            An AE that does not follow a reasonable temporal sequence from administration of a drug and/or that can reasonably be explained by other factors, such as underlying diseases, complications, concomitant medications, and concurrent treatments.

#### **10.1.8    Relationship to Study Procedures**

Relationship (causality) to study procedures should be determined for all AEs.

The relationship should be assessed as Related if the investigator considers that there is reasonable possibility that an event is due to a study procedure. Otherwise, the relationship should be assessed as Not Related.

#### **10.1.9    Start Date**

The start date of the AE is the date that the first signs/symptoms were noted by the subject and/or investigator.

The start date of AEs will be determined using the following criteria:

AEs	Start Date
Any signs/symptoms/diseases (diagnosis)	The date that the first signs/symptoms/diseases were noted by the subject and/or the investigator should be recorded.
Asymptomatic diseases	The date when examination was performed for diagnosis and diagnosis was confirmed should be recorded.
Worsening or complication of concurrent medical conditions or any signs/symptoms/diseases before treatment	The date when diagnosis was confirmed should also be recorded even when values or findings showed previous values or findings, or the onset time can be estimated.
The examination after start of the study drug showed abnormal values/findings.	The date that a worsening or complication of the condition was noted first by the subject and/or the investigator should be recorded.
The examination at the start of the study drug showed abnormal values/findings and the subsequent examinations showed worsening of the symptoms.	The date of examination when an abnormal value or findings that was judged to be clinically significant was noted should be recorded.
	The date of examination when apparent elevation, reduction, increase, or decrease was confirmed in judgment according to the trends in those values or findings should be recorded.

#### 10.1.10 Stop Date

The stop date of the AE is the date at which the subject recovered, the event resolved but with sequelae or the subject died.

#### 10.1.11 Frequency

Episodic AEs (eg, vomiting) or those that occur repeatedly over a period of consecutive days are intermittent. All other events are continuous.

#### 10.1.12 Action Concerning Study Drug

- Drug withdrawn – a study drug is stopped due to the particular AE.
- Dose not changed – the particular AE did not require stopping a study drug.
- Unknown – only to be used if it has not been possible to determine what action has been taken.
- Not Applicable – a study drug was stopped for a reason other than the particular AE eg, the study has been terminated, the subject died, dosing with study drug was already stopped before the onset of the AE.
- Dose Reduced – the dose was reduced due to the particular AE.
- Dose Increased – the dose was increased due to the particular AE.

- Dose Interrupted – the dose was interrupted due to the particular AE.

### **10.1.13 Outcome**

- Recovered/Resolved – Subject returned to first assessment status with respect to the AE.
- Recovering/Resolving – the intensity is lowered by 1 or more stages: the diagnosis or signs/symptoms has almost disappeared; the abnormal laboratory value improved but has not returned to the normal range or to baseline; the subject died from a cause other than the particular AE with the condition remaining “recovering/resolving”.
- Not recovered/not resolved – there is no change in the diagnosis, signs, or symptoms; the intensity of the diagnosis, signs/ symptoms or laboratory value on the last day of the observed study period has got worse than when it started; is an irreversible congenital anomaly; the subject died from another cause with the particular AE state remaining “Not recovered/not resolved”.
- Resolved with sequelae – the subject recovered from an acute AE but was left with permanent/significant impairment (eg, recovered from a cardiovascular accident but with some persisting paresis).
- Fatal – the AEs that are considered as the cause of death.
- Unknown – the course of the AE cannot be followed up due to hospital change or residence change at the end of the subject’s participation in the study.

## **10.2 Procedures**

### **10.2.1 Collection and Reporting of AEs**

#### *10.2.1.1 AE Collection Period*

Collection of AEs will commence from the time that the subject signs the informed consent and will continue until the end of safety follow-up.

#### *10.2.1.2 AE Reporting*

At each study visit, the investigator will assess whether any subjective AEs have occurred. A neutral question, such as “How have you been feeling since your last visit?” may be asked. Subjects may report AEs occurring at any other time during the study. Subjects experiencing a serious AE must be monitored until the symptoms subside and any clinically relevant changes in laboratory values have returned to baseline or there is a satisfactory explanation for the change.

All subjects experiencing AEs, whether considered associated with the use of the study drug or not, must be monitored until the symptoms subside and any clinically relevant changes in laboratory values have returned to baseline or until there is a satisfactory explanation for the changes observed. All AEs will be documented in the AE page of the eCRF, whether or not the

investigator concludes that the event is related to the drug treatment. The following information will be documented for each event:

1. Event term.
2. Start and stop date and time.
3. Frequency.
4. Intensity.
5. Investigator's opinion of the causal relationship between the event and administration of study drug(s) (related or not related).
6. Investigator's opinion of the causal relationship to study procedure(s), including the details of the suspected procedure.
7. Action concerning study drug.
8. Outcome of event.
9. Seriousness.

Patient eDiary/questionnaire will not be used as a primary means to collect AEs. However, should the investigator become aware of a potential AE through the information collected with these instruments, then proper follow-up with the subject for medical evaluation should be undertaken. Through this follow-up if it is determined that an AE not previously reported has been identified, normal reporting requirements should be applied.

### **10.2.2 Collection and Reporting of SAEs**

All AEs spontaneously reported by the subject or in response to an open question from study personnel or revealed by observation, physical examination, or other diagnostic procedures will be recorded on the appropriate page of the eCRF (see [Section 10.2.1](#) for the period of observation). Any clinically relevant deterioration in laboratory assessments or other clinical finding is considered an AE. When possible, signs and symptoms indicating a common underlying pathology should be noted as a single comprehensive event.

An SAE should be reported by the investigator to the sponsor within 24 hours/1 business day of the SAE occurrence, along with any relevant information. This will be done by transmitting an electronic data capture (EDC) SAE report. If transmission of an EDC SAE report is not feasible within 24 hours/1 business day of the SAE occurrence, the completed Takeda paper-based SAE form should be submitted to the sponsor/the Emergency Reception Center for Safety Information appropriate personnel (see annexes) 24 hours/1 business day of the SAE occurrence. The information should be completed as fully as possible but contain, at a minimum:

- A short description of the event and the reason why the event is categorized as serious.
- Subject ID number.
- Investigator's name.

- Name of the study drug(s).
- Causality assessment.

If paper-based SAEs are submitted, EDC/RAVE must be updated as soon as possible with the appropriate information.

- When reporting SAEs or pregnancy, SAE report form or pregnancy report form those are provided by the sponsor or by the institutions must be used.
- After the initial information of SAEs is reported to the sponsor, the initial SAE report form (original wet-ink) must be submitted to the sponsor in Japan. Also, if applicable, copy of related documents should be submitted to the sponsor as soon as possible, once they are available. The investigator should report detailed information without delay after notification of initial information. Additional detailed follow-up data surrounding the SAEs that becomes available following the initial report should be communicated through the same channels as outlined above.
- An operator of the Emergency Center for Safety Information is available for contact 24 hours a day and 365 days a year.

Emergency Center for Safety Information (available 24 hours 365 days)  
[REDACTED]  
[REDACTED]  
[REDACTED]

Any SAE spontaneously reported to the investigator following the AE collection period should be reported to the sponsor if considered related to study participation.

### **10.3 Follow-up of SAEs**

If information not available at the time of the first report becomes available at a later date, the investigator will transmit a follow-up EDC SAE report or a paper-based SAE form in an EDC SAE report is not feasible (copy) or provide other written documentation and transmit it immediately. Copies of any relevant data from the hospital notes (eg, ECGs, laboratory tests, discharge summary, postmortem results) should be sent to the addressee, if requested.

All SAEs should be followed up until resolution or permanent outcome of the event. The timelines and procedure for follow-up reports are the same as those for the initial report.

#### **10.3.1 Safety Reporting to Investigators, IRBs, and Regulatory Authorities**

The sponsor will be responsible for reporting all suspected unexpected serious adverse reactions (SUSARs) and any other applicable SAEs to regulatory authorities, investigators, IRBs, and the head of the study site, as applicable, in accordance with national regulations in the countries where the study is conducted. Relative to the first awareness of the event by/or further provision to the sponsor or sponsor's designee, SUSARs will be submitted to the regulatory authorities as

expedited report within 7 days for fatal and life-threatening events and 15 days for other serious events, unless otherwise required by national regulations. The sponsor will also prepare an expedited report for other safety issues where these might materially alter the current benefit-risk assessment of a study drug/sponsor-supplied drug or that would be sufficient to consider changes in the study drug/sponsor-supplied drug administration or in the overall conduct of the trial. The study site also will forward a copy of all expedited reports to his or her IRB.

## **10.4 Safety Monitoring Rules**

### **10.4.1 General Guidelines**

The following guidelines are provided for the monitoring of selected laboratory parameters.

**Confirmation Guidance:** At any time during the study, the initial clinical laboratory results meeting the safety monitoring criteria presented below must be confirmed by performing measurements on new specimens (retest).

Retests should be conducted by the central laboratory. Retests at a local laboratory are acceptable on an as-needed basis. Local laboratory results are sent to the investigator and medical monitor of the sponsor for review (these should include the normal range of the local laboratory).

Retest collection should take place within 48 to 72 hours of the availability of the initial findings of potential concern. The results from the retest must be available prior to the next scheduled study visit or subject contact.

The baseline values for the purpose of the safety monitoring are the average between the value obtained during the screening visit (Visit 1) and the baseline visit (Week 0/Visit 2), unless a confounder (eg, intercurrent illness) causes variability outside what is expected for the underlying disease based on the investigator's judgment (in which case a third value will need to be obtained).

If the confirmed laboratory results or the symptom meets the criteria written in [Sections 10.4.3, 10.4.5, 10.4.6, and 10.4.7](#), administration of study drug should be interrupted. Once the symptom is improved, administration of study drug may be restarted at the MTD after consultation with the medical monitor. Unless otherwise specified, there is no maximum number of restart. If the investigator has concerns about restarting at the MTD, dose reduction is allowed after discussion with the medical monitor.

### **10.4.2 Close Monitoring Criteria for Liver Parameters**

[Table 10.a](#) provides the criteria for close monitoring of liver parameters.

**Table 10.a Close Monitoring Criteria for Treatment-Emergent Elevated ALT and TSB**

Parameter	Baseline Value	Close Monitoring Criteria
ALT	$\leq 30$ U/L	$\geq 100$ U/L
	$>30$ to $\leq 150$ U/L	$>3 \times BL$ or $\geq 250$ U/L whichever comes first
	$>150$ to $\leq 450$ U/L	$\geq (BL + 100$ U/L)
TSB	Any	$\geq (BL + 3$ mg/dL)

ALT=alanine aminotransferase; BL=baseline; TSB=total serum bilirubin.

**Frequency of Repeat Measurements:** Subjects with a confirmed ALT or total serum bilirubin (TSB) level that is continuing to rise after meeting the close monitoring criteria should have their liver chemistry retested as clinically indicated, until levels stabilize or begin to recover.

**Further Investigation into Liver Chemistry Elevations:** For subjects with a confirmed increase in ALT or TSB level, meeting the close monitoring criteria, the following investigations should be considered, as clinically indicated:

- Close and frequent monitoring of liver enzyme and serum bilirubin tests as clinically indicated. Frequency of retesting can decrease if abnormalities stabilize, recover, or the study drug has been interrupted or discontinued and the subject has no symptomatic manifestations of hepatitis or immunological reaction.
- Symptoms as well as prior, current, and intercurrent diseases/illnesses.
- Use of or recent change in use of concomitant treatment (including non-prescription medications, herbal and dietary supplement preparations), alcohol use, recreational drug use, and special diets.
- History for exposure to environmental chemical agents and travel.
- Serology for viral hepatitis (hepatitis A virus immunoglobulin M [HAV IgM], hepatitis B virus surface antigen [HBs Ag], hepatitis C virus [HCV] antibody, HCV ribonucleic acid [RNA], cytomegalovirus immunoglobulin M [CMV IgM], and Epstein-Barr virus [EBV] antibody panel).
- Serology for autoimmune hepatitis (eg, antinuclear antibody [ANA]).
- AST, creatine phosphokinase (CPK), and lactate dehydrogenase (LDH).
- CBC with differential blood count (eosinophils).
- Reticulocyte count, prothrombin time (PT)/INR.

Additional investigations of liver parameters, including gastroenterology/hepatology consultations, and/or hepatic imaging, may be performed at the discretion of the investigator, in consultation with the medical monitor.

#### 10.4.3 Guidelines for Interruption of Study Drug for Specific Liver Parameters

If the confirmed laboratory results meet any of the criteria below and the event is without an alternative explanation (ie, intercurrent illness, disease progression, natural history of the disease), interruption of study drug should be considered:

1. The close monitoring criteria of both ALT and TSB are met simultaneously.
- OR
2. An increase of ALT or TSB is accompanied by signs and symptoms (eg, nausea/vomiting, right upper quadrant pain) or an immunological reaction (eg, rash, >5% eosinophilia, fever).
3. The following thresholds are met for either ALT or TSB (see [Table 10.b](#)):

**Table 10.b Guidelines for Interruption of Study Drug for Specific Liver Parameters**

Parameter	Baseline value	Observed change threshold
ALT	$\leq 30$ U/L	$\geq 300$ U/L
	$>30$ to $\leq 150$ U/L	$>(5 \times BL \text{ AND } 300 \text{ U/L}) \text{ OR } \geq 450 \text{ U/L}$ whichever comes first
	$>150$ to $\leq 450$ U/L	$\geq(BL + 300 \text{ U/L})$
TSB	Any	$\geq(BL + 5 \text{ mg/dL})$

ALT=alanine aminotransferase; BL=baseline; TSB=total serum bilirubin.

Frequency of Repeat Measurements: Subjects with a confirmed ALT or TSB level meeting interruption criteria should have their liver chemistry tests retested every 72 hours or as clinically indicated, until levels stabilize or begin to recover.

Further Investigation for Increased Liver Chemistry Results: For subjects with a confirmed increase in ALT or TSB level above the threshold, the investigations outlined in [Section 10.4.2](#) should be considered, as clinically indicated.

Study drug may be restarted as long as the subject does not meet the dosing interruption criteria based on retest, does not meet criteria outlined in [Section 10.4.4](#), liver parameters have returned to or near baseline, and an alternative explanation was found for the increased liver parameter (ie, intercurrent illness, disease progression, or natural history of the underlying disease). The investigator and the medical monitor or qualified designee should confer as to whether additional close monitoring is needed.

#### **10.4.4 Rules for Study Drug Discontinuation Following Abnormalities of Liver Parameters**

Study drug should **not** be restarted:

- If the subject had a probable drug-induced liver injury (DILI) in the opinion of the investigator and medical monitor.
- If the subject reports signs/symptoms of acute hepatitis, liver decompensation (ie, variceal hemorrhage, ascites, hepatic encephalopathy) or hypersensitivity reaction.
- If the subject had liver parameters elevations meeting criteria in [Section 10.4.3](#) without alternative explanations or that are inconsistent with the natural history of the disease.
- After meeting stopping criteria subsequent to a re-challenge (ie, meeting stopping criteria after re-introduction of study drug) that is likely related to study drug.
- After 2 previous interruptions for safety reasons, unless there is a compelling reason why the subject should continue with dosing (ie, interruptions were due to disease progression, natural history, intercurrent illness) and provided that the subject is still compliant with the study protocol as per [Section 8.2](#).

If study drug is permanently discontinued, the subject will be discontinued from the study and will be expected to complete the ET study procedures.

#### **10.4.5 Safety Monitoring for LSVs**

The LSV status will be assessed at every study visit per the schedule of assessments (refer to [Appendix A](#)); blood samples will be obtained at the study visit before the daily dose of vitamins is administered (refer to [Appendix B](#)).

In subjects with LSV deficiency, study drug must be interrupted if clinical symptoms of deficiency occur. Clinical symptoms include, but are not limited to:

- Vitamin A: Night blindness, degeneration of the retina, xerophthalmia, follicular hyperkeratosis, keratomalacia, or Bitot's spots.
- Vitamin D: Rickets, osteomalacia, costochondral beading, epiphyseal enlargement, cranial bossing, bowed legs.
- Vitamin E: Numbness/tingling, decreased deep tendon reflexes, hemolytic anemia, limited extraocular movements, especially upward gaze.
- Vitamin K: Easy bruising, excessive bleeding (eg, epistaxis), blood in the urine or stool, anemia.

Subjects may restart dosing once clinical symptoms resolve and LSV levels begin to improve unless the subject has been previously discontinued for the same symptomatic LSV deficiency. Each subject may be re-challenged after symptomatic LSV deficiency only twice.

In the event of a confirmed level that falls either below the subject's baseline or below the lower limit of normal (refer to central laboratory manual), whichever is lower, for a vitamin (25-hydroxy vitamin D, retinol, RBP,  $\alpha$ -tocopherol), or INR (as a proxy for vitamin K status), without clinical symptoms of deficiency, the investigator should make the appropriate modification to the subject's vitamin supplementation regimen (see also [Section 10.4.6](#) for INR monitoring).

Doses should be increased, as clinically indicated, to optimize the LSV levels. Parenteral formulations should be used (where available) if enteral supplements are unsuccessful at improving LSV deficiency.

The response to the change in regimen will be assessed at the next scheduled on-site study visit. LSV supplements are escalated in monthly intervals over a 3-month period. If during this period the LSV levels are persistently below the subject's baseline value or the lower limit of normal, whichever is lower, and there is an absence of clinical symptoms, the investigator will be given the option of permanent withdrawal of the subject from the study.

#### **10.4.6 Safety Monitoring for Coagulation Panel Results**

In the event of a confirmed laboratory result for INR  $>1.5$  despite adequate vitamin K supplementation, the investigator and the medical monitor may consider a temporary interruption of study drug. Dosing may resume when the INR falls below 1.5 or returns to the subject's baseline level.

#### **10.4.7 Study Medication Discontinuation Rules for Diarrhea**

Study drug should be discontinued if a subject has severe diarrhea that requires hospitalization and/or an IV or nutritional supplementation or leads to severe electrolyte disturbances.

### **10.5 Product Complaints**

Product complaint is a verbal, written, or electronic expression that implies dissatisfaction regarding the identity, strength, purity, quality, or stability of a drug product. Individuals who identify a potential product complaint situation should immediately report this via the phone numbers or email addresses provided in the "Pharmacy Manual".

## **11.0 STUDY-SPECIFIC COMMITTEES**

Because it is an unblinded, small-scale, and late phase clinical study conducted with thorough safety information available in advance, Data Safety Monitoring Board (DSMB)/Data Monitoring Committee (DMC) and other review committees will not be established for this study.

## **12.0 DATA HANDLING AND RECORDKEEPING**

The full details of procedures for data handling will be documented in the Data Management Plan. AEs, medical history, and concurrent medical conditions will be coded using the Medical

Dictionary for Regulatory Activities (MedDRA). Drugs will be coded using the World Health Organization (WHO) Drug Dictionary/ Japanese Drug Dictionary.

## **12.1 eCRFs**

Completed eCRFs are required for each subject who signs an informed consent.

The sponsor or its designee will supply study sites with access to eCRFs. The sponsor will make arrangements to train appropriate site staff in the use of the eCRF. These forms are used to transmit the information collected in the performance of this study to the sponsor and regulatory authorities. eCRFs must be completed in English. Data are transcribed directly onto eCRFs.

Corrections are recorded in an audit trail that captures the old information, the new information, ID of the person making the correction, the date the correction was made, and the reason for change. Reasons for significant corrections should additionally be included.

The principal investigator must review the eCRFs for completeness and accuracy and must e-sign the appropriate eCRFs as indicated. Furthermore, the investigator must retain full responsibility for the accuracy and authenticity of all data entered on the eCRFs.

The following data will not be recorded into the eCRFs:

1. BMI.
2. Laboratory test values (except urine pregnancy test).  
These samples could be examined at sites, if the subjects are too small to collect enough amount of blood for the central laboratory, depending on the investigator's decision (refer to [Appendix B](#)).
3. Serum concentrations of TAK-625.
4. Itch Reported Outcome.
5. Drug Compliance.

After the lock of the study database, any change of, modification of or addition to the data on the eCRFs should be made by the investigator with use of change and modification records of the eCRFs/eCRFs (Data Clarification Form) provided by the sponsor. The principal investigator must review the data change for completeness and accuracy, and must sign, or sign and seal, and date.

eCRFs will be reviewed for completeness and acceptability at the study site during periodic visits by the sponsor or its designee. The sponsor or its designee will be permitted to review the subject's medical and hospital records pertinent to the study to ensure accuracy of the eCRFs. The completed eCRFs are the sole property of the sponsor and should not be made available in any form to third parties, except for authorized representatives of appropriate governmental health or regulatory authorities, without written permission of the sponsor.

Unscheduled assessments (eg, laboratory values) are not required to be collected in the eCRF except for those that are directly relevant to the monitoring of an AE/SAE; collection of other values may be requested by the sponsor.

## **12.2 Record Retention**

The investigator and the head of the study site agree to keep the records stipulated in [Section 12.1](#) and those documents that include (but are not limited to) the study-specific documents, the ID log of all participating subjects, medical records, all original signed and dated informed consent forms, electronic copy of eCRFs, including the audit trail, and detailed records of drug disposition to enable evaluations or audits from regulatory authorities, the sponsor or its designees.

The investigator and the head of the study site are required to retain essential relevant documents until the day specified as 1) or 2) below, whichever comes later. After the marketing approval of TAK-625 in Japan, the term of record retention shall expire on the day when a reexamination or reevaluation of TAK-625 is completed, instead of the day specified as of 1) and 2), if the study is shifted to a post-marketing study. However, if the sponsor requests a longer time period for retention, the head of the study site should discuss how long and how to retain those documents with the sponsor.

1. The day on which marketing approval of the study drug is obtained (or the day 3 years after the date of notification in the case that the investigation is discontinued).
2. The day 3 years after the date of ET or completion of the study.

In addition, the investigator and the head of the study site should retain the essential relevant documents until the receipt of a sponsor-issued notification to state the retention is no longer required.

## **13.0 STATISTICAL METHODS**

### **13.1 Statistical and Analytical Plans**

A SAP will be prepared and finalized prior to database lock. This document will provide further details regarding the definition of analysis endpoints and analysis methodology to address all study objectives.

Statistical analyses will be performed using all subjects' data up to Week 22 after the data are locked for marketing application. Additionally, statistical analyses will also be performed for marketing application at the time when the data are locked after all subjects complete Week 48, using all subjects' data up to and including Week 48. Furthermore, statistical analyses will also be performed using all subjects' data up to the end of the study after the data are locked.

A data review will be conducted prior to database lock. This review will assess the accuracy and completeness of the study database, subject evaluability, and appropriateness of the planned statistical methods.

### **13.1.1 Analysis Sets**

Four kinds of analysis sets are defined in this study. The ITT, the main analysis set used for primary efficacy endpoint, will be defined as below.

- ITT: all subjects who received at least one dose of study drug.
- MITT: all subjects who received study drug through Week 18, and had a reduction from baseline in sBA levels of  $\geq 50\%$  at the Week 12 or Week 18 measurement.
- Per protocol analysis set (PPS): all ITT subjects who did not have any of the major protocol deviations and whose primary endpoint was evaluable.
- Safety analysis set: all subjects who received at least one dose of study drug.

### **13.1.2 Analysis of Demographics and Other Baseline Characteristics**

Demographics and other baseline characteristics will be summarized using the ITT.

### **13.1.3 Efficacy Analysis**

#### *13.1.3.1 Primary Endpoint*

##### Primary Analysis:

Descriptive statistics and two-sided 95% confidence interval (CI) of mean will be provided based on the ITT.

##### Secondary Analysis:

For supportive analysis, the same analysis as the primary analysis will be performed using the MITT and the PPS to confirm robustness of the results.


#### *13.1.3.2 Key Secondary Endpoints and Other Secondary Endpoints*

##### Analytical Methods for Key Secondary Endpoints

Descriptive statistics and two-sided 95% CI of mean will be provided based on the ITT. For supportive analysis, the same analysis as the above analysis will be performed using the PPS to confirm robustness of the results.

##### Analytical Methods for Secondary Endpoints

Descriptive statistics and two-sided 95% CI of mean will be provided based on the ITT.



#### *13.1.3.4 Significance Level and Confidence Coefficient*

- Significance Level: 5% (two-sided test).

- Confidence coefficient: 95% (two-sided).

### **13.1.4 PK Analysis**

The following analysis will be performed for the safety analysis set.

Plasma concentrations of TAK-625 will be summarized by each scheduled sampling time and visit using descriptive statistics.

### **13.1.5 Safety Analysis**

The following analysis will be performed for the safety analysis set.

#### *13.1.5.1 TEAEs*

A TEAE is defined as an AE whose date of onset occurs on or after the start of study drug.

TEAEs will be coded using the MedDRA dictionary. The frequency distribution will be provided using the system organ class and the preferred term as follows:

- The frequency of all TEAEs.
- The frequency of drug-related TEAEs.
- The frequency of TEAEs by intensity.
- The frequency of drug-related TEAEs by intensity.
- The frequency of TEAEs leading to study drug discontinuation.
- The frequency of serious TEAEs.
- The frequency of TEAEs of clinical interest.

#### *13.1.5.2 Clinical Laboratory Results, Vital Signs, ECGs, and Physical Examination Findings (Including Body Weight, Height, and BMI)*

For continuous endpoints, the observed values and the changes from baseline will be summarized for each visit using descriptive statistics. Case plots will also be presented for the observed values.

For categorical endpoints, shift tables showing the number of subjects in each category at baseline and each post-baseline visit will be provided.

## **13.2 Interim Analysis**

This study has no criteria for ET (i.e., neither efficacy nor futility stop).

Statistical analyses will be performed using all subjects' data up to Weeks 22 and 48 after the data are locked for marketing application. Additionally, statistical analyses will also be performed using all subjects' data up to the end of the study after the data are locked.

### **13.3 Determination of Sample Size**

ALGS is a rare disease. The targeted sample size is approximately 5 subjects based on enrollment feasibility of this population in Japan, rather than power calculation.

### **13.4 Other Statistical Considerations**

Other details (eg, methods of data transformation, handling of missing data, and so on) will be described in the SAP.

## **14.0 QUALITY CONTROL AND QUALITY ASSURANCE**

### **14.1 Study-Site Monitoring Visits**

Monitoring visits to the study site will be made periodically during the study to ensure that all aspects of the protocol are followed. Source documents will be reviewed for verification of data recorded on the eCRFs. Source documents are defined as original documents, data, and records. The investigator and the study site/head of the study site guarantee access to source documents by the sponsor or its designee (contract research organization [CRO]) and by the IRB.

All aspects of the study and its documentation will be subject to review by the sponsor or the sponsor's designee (as long as blinding is not jeopardized), including but not limited to the Investigator's Binder, study drug, subject medical records, informed consent documentation, documentation of subject authorization to use personal health information and review of eCRFs and associated source documents. It is important that the investigator and other study personnel are available during the monitoring visits and that sufficient time is devoted to the process.

Alternative approaches may be used to ensure data quality, data integrity, and subject safety (eg, remote source data review/source data verification via phone or video) as permitted by regional and local regulations. Additional details are in the monitoring plan.

### **14.2 Protocol Deviations**

The investigator can deviate and change from the protocol for any medically unavoidable reason, for example, to eliminate an immediate hazard to study subjects, without a prior written agreement with the sponsor or a prior approval from IRB. In the event of a deviation or change, the principal investigator should notify the sponsor and the head of the study site of the deviation or change and its reason in a written form, and then retain a copy of the written form. When necessary, the principal investigator may consult and agree with the sponsor on a protocol amendment. If the protocol amendment is appropriate, the amendment proposal should be submitted to the head of the study site as soon as possible and an approval from IRB should be obtained.

The investigator should document all protocol deviations.

### 14.3 Quality Assurance Audits and Regulatory Agency Inspections

The study site also may be subject to quality assurance audits by the sponsor or designees. In this circumstance, the sponsor-designated auditor will contact the site in advance to arrange an auditing visit. The auditor may ask to visit the facilities where laboratory samples are collected, where the medication is stored and prepared, and any other facility used during the study. In addition, there is the possibility that this study may be inspected by regulatory agencies, including those of foreign governments (eg, the US FDA, the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency [MHRA], the Pharmaceuticals and Medical Devices Agency [PMDA] of Japan). If the study site is contacted for an inspection by a regulatory body, the sponsor should be notified immediately. The investigator and study site/head of the study site guarantee access for quality assurance auditors to all study documents as described in [Section 14.1](#).

## 15.0 ETHICAL ASPECTS OF THE STUDY

This study will be conducted with the highest respect for the individual participants (ie, subjects) according to the protocol, the ethical principles that have their origin in the Declaration of Helsinki, and the International Council for Harmonisation (ICH) Harmonised Tripartite Guideline for GCP. Each investigator will conduct the study according to applicable local or regional regulatory requirements and align his or her conduct in accordance with the “Responsibilities of the Investigator” that are listed in [Appendix I](#). The principles of Helsinki are addressed through the protocol and through appendices containing requirements for informed consent and investigator responsibilities.

### 15.1 IRB Approval

The sponsor or designee will supply relevant documents for submission to the respective IRB for the protocol’s review and approval. This protocol, the IB, a copy of the informed consent form, and, if applicable, subject recruitment materials and/or advertisements and other documents required by all applicable laws and regulations, must be submitted to a central or local IRB for approval. The IRB’s written approval of the protocol and subject informed consent must be obtained and submitted to the sponsor or designee before commencement of the study (ie, before shipment of the sponsor-supplied drug or study-specific screening activity/signing a contract for the clinical study). The IRB approval must refer to the study by exact protocol title, number, and version date; identify versions of other documents (eg, informed consent form) reviewed; and state the approval date. If required by country or regional regulations or procedures, approval from the competent regulatory authority will be obtained before commencement of the study or implementation of a substantial amendment. The sponsor will ship drug/notify site once the sponsor has confirmed the adequacy of site regulatory documentation. Until the site receives drug/notification no protocol activities, including screening may occur.

Study sites must adhere to all requirements stipulated by their respective IRB. This may include notification to the IRB regarding protocol amendments, updates to the informed consent form, recruitment materials intended for viewing by subjects, local safety reporting requirements,

reports, and updates regarding the ongoing review of the study at intervals specified by the respective IRB, and submission of the investigator's final status report to IRB. All IRB approvals and relevant documentation for these items must be provided to the sponsor or designee.

Subject incentives should not exert undue influence for participation. Payments to subjects must be approved by the IRB and sponsor.

## **15.2 Subject Information, Informed Consent, and Subject Authorization**

Written consent documents will embody the elements of informed consent as described in the Declaration of Helsinki and the ICH Guidelines for GCP and will be in accordance with all applicable laws and regulations. The informed consent form, subject authorization form (if applicable), and subject information sheet (if applicable) describe the planned and permitted uses, transfers, and disclosures of the subject's personal and personal health information for purposes of conducting the study, including the use of electronic devices and associated technologies (if applicable). The informed consent form and the subject information sheet (if applicable) further explain the nature of the study, its objectives, and potential risks and benefits, and the date informed consent is given. The informed consent form will detail the requirements of the subject and the fact that he or she is free to withdraw at any time without giving a reason and without prejudice to his or her further medical care.

The investigator is responsible for the preparation, content, and IRB approval of the informed consent form and if applicable, the subject authorization form. The informed consent form, subject authorization form (if applicable), and subject information sheet (if applicable) must be approved by both the IRB and the sponsor before use.

The informed consent form, subject authorization form (if applicable), and subject information sheet (if applicable) must be written in a language fully comprehensible to the prospective subject. It is the responsibility of the investigator to explain the detailed elements of the informed consent form, subject authorization form (if applicable), and subject information sheet (if applicable) to the subject. Information should be given in both oral and written form whenever possible and in the manner deemed appropriate by the IRB.

If the subjects are under 18 years of age, the investigator is responsible for obtaining written informed consent not only from the under-aged subjects, but also from their legally acceptable representatives. If the subject is not capable of rendering adequate written informed consent, then the subject's legally acceptable representative may provide such consent for the subject in accordance with applicable laws and regulations.

The subject, or the subject's legally acceptable representative, must be given ample opportunity to: (1) inquire about details of the study and (2) decide whether or not to participate in the study. If the subject, or the subject's legally acceptable representative, determines he or she will participate in the study, then the informed consent form and subject authorization form (if applicable) must be signed and dated by the subject, or the subject's legally acceptable representative, at the time of consent and prior to the subject entering into the study. The subject or the subject's legally acceptable representative should be instructed to sign using their legal

names, not nicknames, using a ballpoint pen with either blue or black ink in the case of written informed consent. The investigator must also sign and date the informed consent form and subject authorization (if applicable) at the time of consent or after receipt of subject signature and before the subject enters the study.

Once signed, the original informed consent form, or certified copy (if applicable), subject authorization form (if applicable), and subject information sheet (if applicable) will be maintained by the study site. The investigator must document the date the subject signs the informed consent in the subject's medical record. Copies of the signed informed consent form, the signed subject authorization form (if applicable), and subject information sheet (if applicable) shall be provided to the subject.

All revised informed consent forms must be reviewed and signed by relevant subjects or the relevant subject's legally acceptable representative in the same manner as the original informed consent. The date the revised consent was obtained should be recorded in the subject's medical record, and the subject should receive a copy of the revised informed consent form.

### 15.3 Subject Confidentiality

The sponsor and designees affirm and uphold the principle of the subject's right to protection against invasion of privacy. Throughout this study, a subject's source data will only be linked to the sponsor's clinical trial database or documentation via a subject ID number. As permitted by all applicable laws and regulations, limited subject attributes, such as sex, age, or date of birth may be used to verify the subject and accuracy of the subject's unique ID number.

In the event that a serious data breach is detected, the sponsor or its designee and the investigator (as applicable) will take appropriate corrective and preventative actions in response. These actions will be documented, and the relevant regulatory agency(ies) will be notified as appropriate. Where appropriate, the relevant individuals materially affected by the breach would also be notified; in the case of study subjects, this would be done through the investigator.

To comply with ICH Guidelines for GCP and to verify compliance with this protocol, the sponsor requires the investigator to permit the monitor or the sponsor's designee, representatives from any regulatory authority (eg, FDA, UK MHRA, PMDA), the sponsor's designated auditors, and the appropriate IRBs to review the subject's original medical records (source data or documents), including, but not limited to, laboratory test result reports, ECG reports, admission and discharge summaries for hospital admissions occurring during a subject's study participation, and autopsy reports. Access to a subject's original medical records requires the specific authorization of the subject as part of the informed consent process (see [Section 15.2](#)).

Copies of any subject source documents that are provided to the sponsor must have certain personally identifiable information removed (ie, subject name, address, and other identifier fields not collected on the subject's eCRF).

## **15.4 Clinical Trial Disclosures and Publication**

### **15.4.1 Clinical Trial Registration and Results Disclosure**

In order to ensure that information on clinical trials reaches the public in a timely manner and to comply with applicable laws, regulations and guidance, Takeda will, at a minimum, register all interventional clinical trials before study start and disclose the results of those trials in a manner and timeframe compliant with Takeda policy and all applicable laws and regulations. Clinical trial registration and results disclosures will occur on ClinicalTrials.gov, other clinical trial registries/databases as required by law, and on Takeda's corporate website(s).

### **15.4.2 Publication**

During and after the study, only the sponsor may make study information available to other study investigators or to regulatory agencies, except as required by law or regulation.

The sponsor may publish any data and information from the study (including data and information generated by the investigator) without the consent of the investigator. Manuscript authorship for any peer-reviewed publication venue (eg, congress, journal) will appropriately reflect contributions to the production, review, and approval of the document.

## **15.5 Insurance and Compensation for Injury**

Each subject in the study must be insured in accordance with the regulations applicable to the site where the subject is participating. If a local underwriter is required, then the sponsor or sponsor's designee will obtain clinical study insurance against the risk of injury to study subjects. Refer to the study site agreement regarding the sponsor's policy on subject compensation and treatment for injury. If the investigator has questions regarding this policy, he or she should contact the sponsor or sponsor's designee.

## **16.0 DISSEMINATION OF NEW INFORMATION**


When new information important to the proper conduct of the clinical study becomes available, such as on diseases, impairment, and deaths suspected to be due to the effect of the study drug, onset of infections suspected to be due to the use of the study drug, and other information related to study drug quality, efficacy, and safety, the sponsors will inform the investigators and heads of study sites in writing in a timely manner.

When the investigator receives information which the investigator judges may affect the intention of subjects to continue participation in the clinical study, the investigator will make available this information immediately to subjects and their legally acceptable representative, to be recorded in writing, and confirm whether the subject will continue to participate in the study.

## 17.0 REFERENCES

1. Elisofon SA, Emerick KM, Sinacore JM, Alonso EM. Health status of patients with Alagille syndrome. *J Pediatr Gastroenterol Nutr.* 2010;51(6):759-65.
2. Imagawa K, Wada H, Tagawa M, Sumazaki R. Alagille syndrome [in Japanese]. *J. New Rem. & Clin.* 2018;67(12):148-52.
3. Kamath BM, Ye W, Goodrich NP, Loomes KM, Romero R, Heubi JE, et al. Outcomes of Childhood Cholestasis in Alagille Syndrome: Results of a Multicenter Observational Study. *Hepatol Commun.* 2020;4(3):387-98.
4. Kamath BM, Baker A, Houwen R, Todorova L, Kerkar N. Systematic Review: The Epidemiology, Natural History, and Burden of Alagille Syndrome. *J Pediatr Gastroenterol Nutr.* 2018;67(2):148-56.
5. Emerick KM, Whitington PF. Partial external biliary diversion for intractable pruritus and xanthomas in Alagille syndrome. *Hepatology.* 2002;35(6):1501-6.
6. Saleh M, Kamath BM, Chitayat D. Alagille syndrome: clinical perspectives. *Appl Clin Genet.* 2016;9:75-82.
7. [REDACTED]
8. Ethical Considerations for Clinical Trials on Medicinal Products Conducted with the Paediatric Population. 2008. Available from: [https://ec.europa.eu/health/system/files/2016-11/ethical\\_considerations\\_en\\_0.pdf](https://ec.europa.eu/health/system/files/2016-11/ethical_considerations_en_0.pdf) [Accessed 09 March 2022].
9. Whitington PF, Whitington GL. Partial external diversion of bile for the treatment of intractable pruritus associated with intrahepatic cholestasis. *Gastroenterology.* 1988;95(1):130-6.

## 18.0 APPENDIX



TAK-625


Study No. TAK-625-3001

Protocol Amendment 02


Page 100 of 114

08 Dec 2022

Proprietary  
Document  
Not for Use




Property of  
Proprietary  
Document  
Not for Use




for use




Property of Takeda: For non-commercial use only and subject to change.




Property of Takeda: For non-commercial use only and  
of Use







Property of Takeda: For non-commercial use only and subject to終了 of Use







Property of Takeda: For non-commercial use only and sub,  
ns of Use












Property of Takeda: For non-commercial use only and subject to change.



Property of Takeda: For non-commercial use only and not for distribution outside Takeda without prior written consent.

of Use

